Successful insertion and expression of a tetracycline transactivator in Anopheles stephensi associated with increased egg production and decreased hatching rate

Successful insertion and expression of a tetracycline transactivator in Anopheles stephensi associated with increased egg production and decreased hatching rate | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Successful insertion and expression of a tetracycline transactivator in Anopheles stephensi associated with increased egg production and decreased hatching rate Ehud Inbar, Ishaan Samantray, Robert T. Alford, Robert A. Harrell, and 6 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-6270709/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 28 Oct, 2025 Read the published version in Parasites & Vectors → Version 1 posted 7 You are reading this latest preprint version Abstract Sanaria® has pioneered production of aseptic, purified, vialed cryopreserved Plasmodium falciparum (Pf) sporozoites (SPZ) as vaccines and for controlled human malaria infections. More than 3,500 individuals have received more than 9,700 injections of PfSPZ, worldwide. The PfSPZ are manufactured in aseptically reared female Anopheles stephensi mosquitoes. Since PfSPZ vaccines are intended primarily for some of the most disadvantaged people in the world, keeping costs low is imperative. One approach to reducing cost of goods is to eliminate male mosquitoes from the production process, thereby doubling the numbers of PfSPZ-producing mosquitoes per unit space. We intend to do this by creating A. stephensi with a male-lethal allele controlled by the tetracycline conditional gene expression system. Herein, we report the first step in this process, the creation of a driver line that expresses the reverse tetracycline transactivator (rtTA). After sub-optimal results using the bZip early embryonic promoter, we produced 3 mosquito driver lines that expressed rtTA from 3 different genomic loci under the early embryonic vasa promoter. Expressing the rtTA under the vasa promoter significantly increased rtTA mRNA levels compared to its level under bZip. We were unable to achieve homozygosity in two of these lines even after 26 generations. In the third line, the insertion was in an intron of a putative juvenile hormone diol kinase gene. Homozygosity was reached in this line after passage through 7 generations, indicating that the inserted vasa-rtTA nucleotides did not interfere with the function of an essential genomic locus. rtTA mRNA expression levels were higher than in the other two lines, supporting the hypothesis that failure to achieve homozygosity was not due to rtTA expression but to insertion position. The homozygous line produced ~ 18% more eggs per female and a hatching rate of larvae from eggs was 39% lower than of wild-type A. stephensi . The next step will be to cross the driver line with an effector line containing a male-linked lethal gene regulated by the tetracycline responsive element (TRE). Anopheles driver line Tetracycline rtTA Figures Figure 1 Figure 2 Figure 3 Figure 4 Background Vector-borne diseases have a devastating impact worldwide, transmitting viruses, bacteria and parasites which account for 17% of all infectious diseases with more than 700,000 death annually ( 1 ). Malaria is caused by Plasmodium parasites which are transmitted by anopheline mosquitoes. In 2023, malaria caused 263 million illnesses and 597,000 deaths, mainly in young children ( 1 ). The dengue virus is transmitted by Aedes mosquitoes which poses a risk for roughly 4 billion people in 132 countries with annual mortality rate of 40,000 individuals ( 1 ). Sanaria’s Plasmodium falciparum (Pf) sporozoites (SPZ) products are composed of live, aseptic, purified cryopreserved PfSPZ ( 2 ). More than 3,500 individuals have received more than 9,700 doses of PfSPZ products in 44 clinical trials in 14 countries in North America, Europe, Africa, and Asia ( 3 – 31 ). Sanaria® PfSPZ vaccines are safe and well tolerated and have achieved 100% efficacy against heterologous controlled human malaria infection at 12 weeks after last dose of vaccine ( 29 ), sustained protection for at least two years against field transmitted malaria in Africa, including 57% protection against Pf infection for two years with no boosting in Mali ( 32 ), and protection for at least 6 months against highly variant Pf parasites in Papua (Indonesian West New Guinea) ( 33 ). In 2025, clinical trials will begin of Sanaria’s 3rd generation vaccine, genetically attenuated PfSPZ-LARC2 Vaccine ( 34 ). Recent research conducted in the Netherlands has demonstrated that a genetically attenuated vaccine strain with just a single deletion of the mei2 gene (GA2) exhibits a vaccine efficacy of approximately 90% and is well-tolerated ( 35 , 36 ). Given that PfSPZ-LARC2 is a double knockout vaccine strain, with deletions in both mei2 and LINUP, we anticipate a similar or potentially greater protective efficacy, possibly achievable with just one dose. All PfSPZ products are currently produced in aseptic Anopheles stephensi mosquitoes. Major drivers of the cost of vaccine are the incubator space and the personnel required for production and management of aseptic A. stephensi . Only female mosquitoes carry the PfSPZ used in PfSPZ vaccines. If males could be eliminated from the manufacturing process, we would be able to produce double the numbers of PfSPZ in the same space and with the same personnel, thereby significantly reducing the cost of goods. The first step in creating “female only” An. stephensi mosquitoes was to generate a driver line for conditional expression. To do this we used a tetracycline-controlled transcription mechanism, one that is central to tetracycline resistance of gram-negative bacteria ( 37 ), and has been adapted to conditionally express genes in different eukaryotic systems, including mammals and insects ( 38 – 42 ). In this system, a gene of interest is regulated by the tetracycline response element (TRE), which consists of multiple units of the tetracycline operator (TetO). Transcription is initiated only when the tetracycline transactivator (tTA), a DNA-binding protein, binds to the TRE ( 38 , 42 , 43 ). There are two main mechanistic adaptations of this system, Tet-On and Tet-off. In the Tet-off system, the tTA is bound to tetracycline or its derivative doxycycline to prevent binding of the tTA to the TRE; when the drug is removed, the tTA binds to the TRE to initiate transcription of the gene of interest. Conversely, in the Tet-on system, the tTA is modified to a reverse tetracycline transactivator (rtTA) which binds to the TRE in the presence of doxycycline to initiate transcription. When the drug is removed the rtTA is released from the TRE and transcription stops ( 38 , 42 , 43 ). The Tet system has been used in vector control approaches to decrease populations of various disease-transmitting vectors, using Release of Insects carrying a Dominant Lethal gene (RIDL). RIDL is an improved version of the classical release of sterile insect technique (SIT) ( 44 ). Male Aedes aegypti mosquitoes carrying lethal genes are released to mate with wild-type females and transmit the lethal genes to future generations. In the absence of tetracycline or doxycycline in the field, lethal genes are induced and the mosquitoes are killed, usually at the early larval stage ( 40 , 41 , 45 – 49 ). Currently, there is an extensive effort to use RIDL to reduce populations of Ae. aegypti to fight the spread of arboviruses including Zika, Yellow Fever and Dengue ( 47 , 50 , 51 ). Our plan is to use the tetracycline conditional expression system to drive expression of a male lethal gene thereby creating “female-only” aseptic mosquitoes for PfSPZ production. Here we report our successful generation of a homozygous driver line of mosquitoes expressing rtTA (Tet-On) to be used to drive expression of a male lethal gene. Methods Mosquito rearing Anopheles stephensi SDA500 were reared at the Insect transformation facility (ITF) of the University of Maryland’s institute for Bioscience and Biotechnology Research (IBBR) in Rockville, MD, at 28 o C, 75% humidity and 12h:12h light:dark cycle with 30-minute dawn and dusk periods. Construction of driver lines: construction of vasa-rtTA in PiggyBac vector and embryo injections The reverse tetracycline transactivator (rtTA) gene, fused to VP16 transcription activation domain was synthesized by GeneScript company (Piscataway NJ, USA). The vasa promoter was amplified from An. stephensi genomic DNA. We assembled vasa-rtTA-SV40 using NEBuilder® HiFi DNA Assembly Cloning Kit (NEB #E5520S). The entire construct was ligated into the piggyBac transposon vector containing mBanana gene under the 3Xp3 promoter ( 52 ) for easy identification of transgenic An. stephensi . The injections were done as described previously ( 53 , 54 ). Briefly, Preblastodermal embryos were injected, 40–60 minutes post embryo collection, with an injection mix consisting of 150 ng/µL of piggyBac vector and 193 ng/µL of piggyBac transposase mRNA in halocarbon oil, as described ( 54 ) DNA work, Splinkerette mapping and RNA work DNA was extracted from individual adult mosquitoes using DNeasy (Qiagen #69504) as described ( 55 ). Splinkerette mapping of transposable elements was done as described for D. melanogaster ( 56 ). Briefly, genomic DNA was digested by BstYI (NEB # R0523S) and the fragments ligated to a Splinkerette element on 5’ and 3’ ends. Fragments containing the insertions were amplified by two cycles of PCR, using the primers from both ends of the PiggyBac insertions to the Splinkerette at the ends of the fragments, as designed [60]. The PCR amplicons were sent for Sanger sequencing and the sequences sequences were aligned against the An. stephensi SDA500 genome at VEuPathDB, VectorBase ( https://vectorbase.org/vectorbase/app/ ). RNA was extracted as described ( 55 ), using Qiagen RNeasy mini kit (Qiagen #74106) according to the manufacturer instructions. Complimentary (c)DNAs were synthesized using the High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher # 4368814) on extracted RNAs. Real-time PCR reactions were done on cDNAs using SensiFAST™ Real-Time PCR Kits (Bioline # BIO-82005). The ribosomal protein S7 was used as a house keeping control ( 55 ). Assessment of fecundity Three days after blood feeding, females were placed individually in plastic Drosophila cylinders containing water and sealed with cotton balls ( 55 ). The mosquitoes were incubated overnight at > 70% humidity, 28 o C. The next day, the mosquitoes were removed from the tubes and the eggs were counted. The larvae were counted in the tubes 1–2 days after egg laying. The larvae hatching rate was determined as the percent larvae per the total number of eggs in each tube. Data were analyzed using GraphPad Prism version 10.2.1 for Windows. Results Generation of An. stephensi driver line, expressing rtTA under the vasa promoter We constructed a driver line in which the reverse tetracycline transactivator (rtTA, Tet-On) was expressed under the early embryonic promoter, bZip. Assessments of rtTA transcript abundance by quantitative (q) RT-PCR revealed very low mRNA levels of rtTA in eggs, ovaries and adults (data not shown). We therefore replaced the bZip promoter with the early embryonic vasa promoter. For this vasa-rtTA construct, an mBanana fluorescent marker, driven by the 3XP3 promoter was placed in the reverse orientation to the vasa-rtTA expression cassette. The construct was placed into a piggybac vector ( 52 ) between two transposon elements (Fig. 1), then mixed with a transposase-expressing vector ( 54 ) and injected into An . stephensi eggs at the early embryonic stage. Out of 854 eggs injected, 45 hatched and 29 (14 males and 15 females) survived to adults. Males (M) and females (F) were sorted and grouped into cages and crossed with the opposite sex of wild type mosquitoes. Larvae of the subsequent generation (G 1 ), were screened using a fluorescent microscope and transgenic larvae expressing mBanana were collected. From the M group, 114 G 1 larvae were mBanana-positive, of which 43 males and 39 females survived to adults. Fifty-six mBanana-positive larvae, 27 males and 29 females, were obtained from the F group, all surviving to adults. To avoid mixing of genotypes, we separated transgenic lines by collecting eggs from 20 individual G 1 M-group females and 14 individual G 1 F-group females. After oviposition, RNA was extracted from the G 1 females and qRT-PCR used to assess rtTA mRNA abundance (data not shown). The rtTA transcription levels under early embryonic vasa and bZip promoters We selected 4 different lines originating from G 1 female mosquitoes (2 from the M-group and 2 from the F-group) with the highest abundance of rtTA mRNA. We compared the rtTA mRNA levels of the 4 mosquito lines (M1F, M2i, F2C and F2e) to that of 3 transgenic lines we had previously created that express rtTA under the early embryonic bZip promoter, M1-2, M3-2 and M3-3. The rtTA mRNA level in bZip-rtTA M1-2 line was used as a reference. The rtTA mRNA abundance in all three bZip-rtTA lines were comparable (Fig. 2a). In the vasa-rtTA lines mRNA abundance was 1,538-, 2,326-, 562- and 380-fold higher in M1f, M2i, F2c and F2e lines, respectively than in reference bZip-rtTA line (M1-2) (Fig. 2a). Line F2e was lost due to an insectary failure. We crossed the transgenic vasa-rtTA M1f, F2c and M2i lines to WT through 4 generations to expand the lines and reduce the number of inserts. Since the vasa promoter can drive expression in the early stages of embryonic development ( 57 ), we assessed rtTA transcript abundance in embryos 1 h after oviposition (Fig. 2b). The mean rtTA mRNA abundance was 1714-, 2,813- and 405-fold higher than in eggs from the bZip-rtTA line M1-2, in the eggs from the M1f, M2i and M1-2 lines respectively. As seen in the adult mosquitoes, the rtTA mRNA abundance in M2i was higher than in all other lines, and significantly higher compared to F2c embryos (Fig. 2a and b). Mapping the transposon-based insertions of the driver construct and generation of homozygous mosquitoes From G 6 onwards, the lines were in-crossed to obtain homozygosity of the insertion. We collected genomic (g)DNA at G 7 and used it to identify the genomic locus of the transposon-based insertion in each line using the Splinkerette PCR protocol (see materials and methods). The sequences were aligned against the An . stephensi genome in VectorBase. In the M1F line, the vasa construct was inserted into supercontig KB664888, position 665,462, which is within an exon in the open reading frame (ORF) of an “Era G-protein-like” (ASTE010067) coding sequence. In the F2c line the insertion was in supercontig KB665088, position 785,341, which is not in any known ORF. In the M2i line, the vasa construct was inserted into supercontig KB665343 position, 382,729, which is within the last intron of a putative juvenile hormone diol kinase gene (ASTE000415). We continued to in-cross the 3 lines through subsequent generations while monitoring the proportion of mBanana expressing larvae in each generation as an indication of their progression toward homozygosity. In the M2i line almost all the larvae were transgenic after G 17 , while in the F2c and M1f lines only about two thirds of the larvae expressed mBanana. We therefore carefully tracked the proportion of mBanana-positive larvae through generations 24, 25 and 26 (Tables 1). All M2i larvae expressed mBanana in generations 24–26. Only 76%, 74% and 80% of M1f larvae and 77%, 72% and 78% of F2c larvae expressed mBanana in generations 24, 25 and 26, respectively. Based on the positions of the inserts in each line, we designed PCR primers flanking the insertions to determine the zygosity level in each line (Fig. 3). All three M1f and F2c tested mosquitoes were heterozygous at G 7 and continued to be heterozygous at G 24 . Two of 3 mosquitoes in the M2i line were homozygous at G 7 (b and c), and 4 of 6 mosquitoes (a, b, d and f) were homozygous at G 24 (Fig. 3). Assessment of potential insertion-related fitness cost To assess the effect of the rtTA expression on fitness, we compared the fecundity in all 3 lines with that of WT An . stephensi . From each line, eggs from up to 100 individual females were counted and the proportion of eggs hatching determined. From the WT line, 83% laid eggs. Likewise, 86% and 84% of the females laid eggs in the M2i and F2c groups, respectively. Only 59 out of 86 (68%) M1f females laid eggs. The geometric mean (GM) number of eggs laid per individual female in the WT line was 145, (95% CI = 133–159). In the M1f line the number of eggs/ female was slightly but not significantly lower [GM = 123, 95% CI = 106–143), while the numbers of eggs laid by M2i (GM = 181, 95% CI = 169–195) and F2c (GM = 190, 95% CI = 175–207) females were significantly higher than those of WT and the M1f line (Fig. 4a). The GM of the percentage larvae hatching in WT was 76% (95% CI = 65–88). Hatching rates were significantly lower in all three driver lines, 38% (95% CI = 45–63) in M1f, 42% (95% CI = 30–59) in M2i, and 53% (95% CI = 45–62) in F2c (Fig. 4b). In the following generation, the number of eggs laid per M2i female (GM = 167, 95% CI = 154–181) was again higher than WT females (GM = 149, 95% CI = 139–159) (Fig. 4c), and the hatching rate in M2i (GM = 55%, 95% CI = 44–70) was significantly lower compared to that of WT (GM = 81, 95% CI = 77–85) (Fig. 4d), confirming the pervious observation (Fig. 4 a&b). Discussion Our long -term goal is to establish a system for conditionally expressing foreign genes in An . stephensi . Our medium-term goal is to use this system to conditionally express a lethal gene in male mosquitoes to increase the efficiency of our manufacturing process. In the present study we created the driver line for the conditional expression that can be crossed with the effector line to generate mosquitoes with the desired phenotype. We evaluated two promoters for driving expression of rtTA. For unknown reasons, transcription of rtTA was minimal under bZip. This finding is consistent with a previous study done in Ae. aegypti , which showed that while the bZip promoter effectively drove strong transcription of the mNG fluorescent marker, it failed to initiate transcription of tTA ( 58 ). In contrast, the vasa promoter facilitated high levels of rtTA expression. The vasa promoter has been shown previously to drive endogenous vasa gene expression as well as exogenous eGFP expression in ovaries, testis and 1–2 h post-oviposition embryos of An. gambiae ( 57 ). We were unable to obtain homozygosity in lines M1f and F2c, while in the 3rd line, M2i, homozygosity was established as early as G 7 . rtTA mRNA expression in M2i was higher than in M1f and F2c, likely due the fact that there was an rtTA encoding gene on both chromosomes, not just one. Thus, it appears that the inability to reach homozygosity in M1f and F2c was not due to rtTA expression but rather to the genomic locus of the insertions. In the M1f line the rtTA insertion was within an exon in a coding gene, Era G-protein-like (ASTE010067), a member of a family of G-proteins associated with signal transduction and involved in many aspects of the life cycles in many organisms. One essential, well known function of G-proteins in insects, including Anophelines, is in the sensing of environmental signals through odorant binding proteins and the response of the insects to those signals ( 59 , 60 ). It is therefore highly likely that ASTE010067 is an essential gene, and the mosquitoes cannot tolerate disruption of both of its copies. In F2c, the insertion was at the 3’ end of supercontig KB665088, in a non-coding region, which may be crucial for mosquito survival. In M2i, the insertion was in an intron of a putative juvenile hormone diol kinase gene (ASTE000415). In the moth, Heortia vitessoides , juvenile hormone diol kinase is involved in hormone recycling and is essential for the development and survival of the moth ( 61 ). The ability to obtain homozygosity suggests that the insertion in the intron did not affect the expression and activity of the gene. Four out of 6 G 24 M2i mosquitoes were homozygous for the insertion, indicating that the insertion was still not fixed in the population. It was therefore surprising that by microscope screening, 100% of the larvae were mBanana positive. It is possible that in M2i there are one or more insertions in genes in addition to the putative juvenile hormone diol kinase gene (ASTE000415) that were not detected by the Splinkerette mapping. The fact that all the larvae were positive by microscopy in three consecutive generations (G 24 -G 26 ) suggests that at least one of the undetected insertions is already fixed in the population and its position is not in an essential locus in the genome. The homozygous line, M2i produced significantly more eggs (24% and 12%) than the WT mosquitoes in two experiments (Fig. 4). However, M2i had a significantly lower (45% and 33%) rate of larval hatching in (Fig. 4). Thus, the efficiency overall of producing larvae was reduced by about 21%. Since the driver line will next be crossed with an effector line, it remains to be seen whether this reduced hatching rate will impact production of adults in the final product. Expression of tTA has been associated with fitness costs in insects. Overexpression in D. melanogaster had a toxic effect on early development in heterozygous progeny due to interference in ubiquitination and protein proteolysis as well as transcriptional squelching ( 41 ). Thus, it was used later as a lethal gene in RIDL systems in Ae. aegypti and D. melanogaster ( 40 , 46 ). The lethal effect of tTAV, a codon-optimized version of tTA, on transcription in D. melanogaster is dependent on the site of the genomic integration. All insertions have negative effects on early development, but each insertion triggers a different transcriptional profile leading to different phenotypes ( 40 ). Based on these observations, Oxitec developed transgenic mosquitoes in which females are being killed in the field by overexpressing the tTA in a positive feedback loop ( 46 , 62 , 63 ). In these mosquitoes, only minimal levels of tTA are being produced when tetracycline is present in the larval diet but when these mosquitoes are released in the field with no tetracycline, the tTA binds to TetO allowing overexpression of the downstream tTA in females, and mortality of subsequent mosquito generations at the early larval stage. Release of these mosquitoes in field studies in the United States and Brazil led to reductions of up to 96% of the mosquito populations ( 47 , 50 ). Conclusions In summary, we successfully completed the first step in creating An . stephensi with a male-lethal allele controlled by a conditional gene expression system. We produced An . stephensi homozygous driver line, M2i, that expresses rtTA under the early embryonic vasa promoter. Egg production by m2i was ~ 18% greater than by WT mosquitoes, and the hatching rate of eggs to larvae ~ 39% lower than in WT mosquitoes. This overall 21% decrease in fecundity is acceptable for moving to the next step which will be to cross the M2i driver line with an effector line carrying a male-lethal gene. In the final product the rtTA transcription factor will bind to the tetracycline responsive element (TRE) in the presence of doxycycline, driving lethal gene expression only in males. Success in step 2 will provide the foundation for crossing the driver line described herein with other lines to conditionally express any target gene in An . stephensi . Declarations Ethics approval and consent to participate: Not applicable Consent for publication: Not applicable Availability of data and materials: All data generated or analyzed during this study are included in this published article. Competing interests E.I., A.E.G., T.V.P, G.J., P.F.B., and S.L.H. are salaried employees of Sanaria Inc., the developer and owner of PfSPZ vaccines, and A.E.G. and P.F.B. were salaried employees of Sanaria Inc. when the work was performed. S.L.H. has a financial interest in Sanaria Inc. No other authors have competing interests. Fundings: This work was funded by the two NIAID-NIH SBIR grants 1R43AI143077 and 5R43AI174393. Author Contributions E.I., R.T.A., R.A.H., A.E.G., T.V.P. and G.J. performed the work and contributed to data collection. E.I., A.E.G., R.A.H., S.L.H. and P.F.B., designed the studies and with T. V. P. supervised the project. E.I., T. V. P. R.A.H., P.F.B. and S.L.H. wrote the manuscript. All authors discussed the results and commented on the manuscript. References Vector-borne diseases [Internet]. World Health Organization 2024 [cited 09/26/2024]. Available from: https://www.who.int/news-room/fact-sheets/detail/vector-borne-diseases#:~:text=Vector% 2Dborne%20diseases%20are%20human,spread%20of%20vector%2Dborne%20diseases. Hoffman SL, Billingsley PF, James E, Richman A, Loyevsky M, Li T, et al. Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hum Vaccin. 2010;6(1):97-106. Sissoko MS, Healy SA, Katile A, Omaswa F, Zaidi I, Gabriel EE, et al. Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial. Lancet Infect Dis. 2017;17(5):498-509. Jongo SA, Shekalage SA, Church LWP, Ruben AJ, Schindler T, Zenklusen I, et al. Safety, Immunogenicity, and Protective Efficacy against Controlled Human Malaria Infection of Plasmodium falciparum Sporozoite Vaccine in Tanzanian Adults. Am J Trop Med Hyg. 2018;99(2):338-49. Olotu A, Urbano V, Hamad A, Eka M, Chemba M, Nyakarungu E, et al. Advancing Global Health through Development and Clinical Trials Partnerships: A Randomized, Placebo-Controlled, Double-Blind Assessment of Safety, Tolerability, and Immunogenicity of Plasmodium falciparum Sporozoites Vaccine for Malaria in Healthy Equatoguinean Men. Am J Trop Med Hyg. 2018;98(1):308-18. Jongo SA, Church LWP, Mtoro AT, Chakravarty S, Ruben AJ, Swanson PA, et al. Safety and Differential Antibody and T-Cell Responses to the Plasmodium falciparum Sporozoite Malaria Vaccine, PfSPZ Vaccine, by Age in Tanzanian Adults, Adolescents, Children, and Infants. Am J Trop Med Hyg. 2019;100(6):1433-44. Roestenberg M, Walk J, van der Boor SC, Langenberg MCC, Hoogerwerf MA, Janse JJ, et al. A double-blind, placebo-controlled phase 1/2a trial of the genetically attenuated malaria vaccine PfSPZ-GA1. Sci Transl Med. 2020;12(544):eaaz5629. Steinhardt LC, Richie TL, Yego R, Akach D, Hamel MJ, Gutman JR, et al. Safety, tolerability, and immunogenicity of PfSPZ Vaccine administered by direct venous inoculation to infants and young children: findings from an age de-escalation, dose-escalation double-blinded randomized, controlled study in western Kenya. Clin Infect Dis. 2020;71(14):1063-71. Jongo SA, Urbano V, Church LWP, Olotu A, Manock SR, Schindler T, et al. Immunogenicity and Protective Efficacy of Radiation-Attenuated and Chemo-Attenuated PfSPZ Vaccines in Equatoguinean Adults. Am J Trop Med Hyg. 2021;104(1):283-93. Sissoko MS, Healy SA, Katile A, Zaidi I, Hu Z, Kamate B, et al. Three dose regimen of PfSPZ Vaccine protects adult Malians against Plasmodium falciparum through an intense transmission season: a randomized, controlled phase I trial. Lancet Infect Dis Nov 18;S1473-3099(21)00332-7. 2021. Oneko M, Steinhardt LC, Yego R, Wiegand RE, Swanson PA, Kc N, et al. Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial. Nat Med. 2021;27(9):1636-45. Epstein JE, Tewari K, Lyke KE, Sim BK, Billingsley PF, Laurens MB, et al. Live attenuated malaria vaccine designed to protect through hepatic CD8+T cell immunity. Science. 2011;334(6055):475-80. Roestenberg M, Bijker EM, Sim BK, Billingsley PF, James ER, Bastiaens GJ, et al. Controlled Human Malaria Infections by Intradermal Injection of Cryopreserved Plasmodium falciparum Sporozoites. Am J Trop Med Hyg. 2013;88(1):5-13. Seder RA, Chang LJ, Enama ME, Zephir KL, Sarwar UN, Gordon IJ, et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science. 2013;341(6152):1359-65. Sheehy SH, Spencer AJ, Douglas AD, Sim BK, Longley RJ, Edwards NJ, et al. Optimising Controlled Human Malaria Infection Studies Using Cryopreserved Parasites Administered by Needle and Syringe. PLoS One. 2013;8(6):e65960. Shekalaghe S, Rutaihwa M, Billingsley PF, Chemba M, Daubenberger CA, James ER, et al. Controlled human malaria infection of Tanzanians by intradermal injection of aseptic, purified, cryopreserved Plasmodium falciparum sporozoites. Am J Trop Med Hyg. 2014;91(3):471-80. Hodgson SH, Juma EA, Salim A, Magiri C, Kimani D, Njenga D, et al. Evaluating Controlled Human Malaria Infection in Kenyan Adults with Varying Degrees of Prior Exposure to Plasmodium falciparum using sporozoites administered by intramuscular injection. Frontiers in Microbiology. 2014;5:686. Bastiaens GJ, van Meer MP, Scholzen A, Obiero JM, Vatanshenassan M, van Grinsven T, et al. Safety, Immunogenicity, and Protective Efficacy of Intradermal Immunization with Aseptic, Purified, Cryopreserved Plasmodium falciparum Sporozoites in Volunteers Under Chloroquine Prophylaxis: A Randomized Controlled Trial. Am J Trop Med Hyg. 2016;94(3):663-73. Gomez-Perez GP, Legarda A, Munoz J, Sim BK, Ballester MR, Dobano C, et al. Controlled human malaria infection by intramuscular and direct venous inoculation of cryopreserved Plasmodium falciparum sporozoites in malaria-naive volunteers: effect of injection volume and dose on infectivity rates. Malar J. 2015;14:306. Lyke KE, Laurens MB, Strauss K, Adams M, Billingsley PF, James E, et al. Optimizing Intradermal Administration of Cryopreserved Plasmodium falciparum Sporozoites in Controlled Human Malaria Infection. Am J Trop Med Hyg. 2015;93(6):1274-84. Mordmüller B, Supan C, Sim KL, Gómez-Pérez GP, Ospina Salazar CL, Held J, et al. Direct venous inoculation of Plasmodium falciparum sporozoites for controlled human malaria infection: a dose-finding trial in two centres. Malar J. 2015;14:117. Ishizuka AS, Lyke KE, DeZure A, Berry AA, Richie TL, Mendoza FH, et al. Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. Nat Med. 2016;22(6):614-23. Epstein JE, Paolino KM, Richie TL, Sedegah M, Singer A, Ruben AJ, et al. Protection against Plasmodium falciparum malaria by PfSPZ Vaccine. JCI Insight. 2017;2(1):e89154. Mordmuller B, Surat G, Lagler H, Chakravarty S, Ishizuka AS, Lalremruata A, et al. Sterile protection against human malaria by chemoattenuated PfSPZ vaccine. Nature. 2017;542(7642):445-9. Lyke KE, Ishizuka AS, Berry AA, Chakravarty S, DeZure A, Enama ME, et al. Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection. Proc Natl Acad Sci U S A. 2017;114(10):2711-6. Lell B, Mordmuller B, Dejon Agobe JC, Honkpehedji J, Zinsou J, Mengue JB, et al. Impact of Sickle Cell Trait and Naturally Acquired Immunity on Uncomplicated Malaria after Controlled Human Malaria Infection in Adults in Gabon. Am J Trop Med Hyg. 2018;98(2):508-15. Oneko M, Cherop YR, Sang T, Gutman JR, Wiegand R, Nyang'au EM, et al. Feasibility of direct venous inoculation of the radiation-attenuated Plasmodium falciparum whole sporozoite vaccine in children and infants in Siaya, western Kenya. Vaccine. 2020;38(29):4592-600. Lyke KE, Singer A, Berry AA, Reyes S, Chakravarty S, James ER, et al. Multidose Priming and Delayed Boosting Improve PfSPZ Vaccine Efficacy against Heterologous P. falciparum Controlled Human Malaria Infection. Clin Infect Dis. 2021;73(7):e2424-e35. Mwakingwe-Omari A, Healy SA, Lane J, Cook DM, Kalhori S, Wyatt C, et al. Two chemoattenuated PfSPZ malaria vaccines induce sterile hepatic immunity. Nature. 2021;595(7866):289-94. Mordmuller B, Sulyok Z, Sulyok M, Molnar Z, Lalremruata A, Calle CL, et al. A PfSPZ vaccine immunization regimen equally protective against homologous and heterologous controlled human malaria infection. NPJ Vaccines. 2022;7(1):100. Sulyok Z, Fendel R, Eder B, Lorenz FR, Kc N, Karnahl M, et al. Heterologous protection against malaria by a simple chemoattenuated PfSPZ vaccine regimen in a randomized trial. Nat Commun. 2021;12(1):2518. Diawara H, Healy SA, Mwakingwe-Omari A, Issiaka D, Diallo A, Traore S, et al. Safety and efficacy of PfSPZ Vaccine against malaria in healthy adults and women anticipating pregnancy in Mali: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect Dis. 2024;24(12):1366-82. Nelwan EJ, Richie hL, Chand K, Indrihutami K, Rachmat A, Chen M-C, et al. Protection of Indonesian soldiers against highly variant Plasmodium falciparum Infection in Papua province, Indonesia, by two PfSPZ vaccines American Society of Tropical Medicine & Hygiene (ASTMH) 2024; New Orleans, LA. Goswami D, Patel H, Betz W, Armstrong J, Camargo N, Patil A, et al. A replication competent Plasmodium falciparum parasite completely attenuated by dual gene deletion. EMBO Mol Med. 2024;16(4):723-54. Lamers OA, Franke-Fayard BM, Koopman JPR, Roozen GV, Janse JJ, Chevalley-Maurel SC, et al. Safety and efficacy of immunization with a late-liver-stage attenuated malaria parasite. N Engl J Med. 2024;391(20):1913-23. Roozen GVT, van Schuijlenburg R, Hensen ADO, Koopman JPR, Lamers OAC, Geurten FJA, et al. Single immunization with genetically attenuated Pf∆mei2 (GA2) parasites by mosquito bite in controlled human malaria infection: a placebo-controlled randomized trial. Nat Med. 2025 Jan 3. doi: 10.1038/s41591-024-03347-2. Online ahead of print. Orth P, Schnappinger D, Hillen W, Saenger W, Hinrichs W. Structural basis of gene regulation by the tetracycline inducible Tet repressor-operator system. Nat Struct Biol. 2000;7(3):215-9. Gossen M, Freundlieb S, Bender G, Muller G, Hillen W, Bujard H. Transcriptional activation by tetracyclines in mammalian cells. Science. 1995;268(5218):1766-9. Lycett GJ, Kafatos FC, Loukeris TG. Conditional expression in the malaria mosquito Anopheles stephensi with Tet-On and Tet-Off systems. Genetics. 2004;167(4):1781-90. Bryk J, Reeves RG, Reed FA, Denton JA. Transcriptional effects of a positive feedback circuit in Drosophila melanogaster. BMC Genomics. 2017;18(1):990. Gong P, Epton MJ, Fu G, Scaife S, Hiscox A, Condon KC, et al. A dominant lethal genetic system for autocidal control of the Mediterranean fruitfly. Nat Biotechnol. 2005;23(4):453-6. Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci U S A. 1992;89(12):5547-51. Gossen M, Bujard H. Studying gene function in eukaryotes by conditional gene inactivation. Annu Rev Genet. 2002;36:153-73. Black WCt, Alphey L, James AA. Why RIDL is not SIT. Trends Parasitol. 2011;27(8):362-70. Fu G, Condon KC, Epton MJ, Gong P, Jin L, Condon GC, et al. Female-specific insect lethality engineered using alternative splicing. Nat Biotechnol. 2007;25(3):353-7. Phuc HK, Andreasen MH, Burton RS, Vass C, Epton MJ, Pape G, et al. Late-acting dominant lethal genetic systems and mosquito control. BMC Biol. 2007;5:11. Waltz E. First genetically modified mosquitoes released in the United States. Nature. 2021;593(7858):175-6. Yan Y, Scott MJ. Building a transgenic sexing strain for genetic control of the Australian sheep blow fly Lucilia cuprina using two lethal effectors. BMC Genet. 2020;21(Suppl 2):141. Bushland RC, Lindquist AW, Knipling EF. Eradication of Screw-Worms through Release of Sterilized Males. Science. 1955;122(3163):287-8. Spinner SAM, Barnes ZH, Puinean AM, Gray P, Dafa'alla T, Phillips CE, et al. New self-sexing Aedes aegypti strain eliminates barriers to scalable and sustainable vector control for governments and communities in dengue-prone environments. Front Bioeng Biotechnol. 2022;10:975786. Carvalho DO, McKemey AR, Garziera L, Lacroix R, Donnelly CA, Alphey L, et al. Suppression of a Field Population of Aedes aegypti in Brazil by Sustained Release of Transgenic Male Mosquitoes. PLoS Negl Trop Dis. 2015;9(7):e0003864. Reid W, Pilitt K, Alford R, Cervantes-Medina A, Yu H, Aluvihare C, et al. An Anopheles stephensi Promoter-Trap: Augmenting Genome Annotation and Functional Genomics. G3 (Bethesda). 2018;8(10):3119-30. Harrell RA, 2nd. Mosquito Embryo Microinjection. Cold Spring Harb Protoc. 2024;2024(7):pdb top107686. Harrell RA, 2nd. Mosquito Embryo Microinjection under Halocarbon Oil or in Aqueous Solution. Cold Spring Harb Protoc. 2024;2024(7):pdb prot108203. Inbar E, Eappen AG, Alford RT, Reid W, Harrell RA, Hosseini M, et al. Knockout of Anopheles stephensi immune gene LRIM1 by CRISPR-Cas9 reveals its unexpected role in reproduction and vector competence. PLoS Pathog. 2021;17(11):e1009770. Potter CJ, Luo L. Splinkerette PCR for mapping transposable elements in Drosophila. PLoS One. 2010;5(4):e10168. Papathanos PA, Windbichler N, Menichelli M, Burt A, Crisanti A. The vasa regulatory region mediates germline expression and maternal transmission of proteins in the malaria mosquito Anopheles gambiae: a versatile tool for genetic control strategies. BMC Mol Biol. 2009;10:65. Kojin BB, Biedler JK, Tu Z, Adelman ZN. Characterization of a female germline and early zygote promoter from the transcription factor bZip1 in the dengue mosquito Aedes aegypti. Parasit Vectors. 2020;13(1):353. Sun JS, Xiao S, Carlson JR. The diverse small proteins called odorant-binding proteins. Open Biol. 2018;8(12):180208. Hill CA, Fox AN, Pitts RJ, Kent LB, Tan PL, Chrystal MA, et al. G protein-coupled receptors in Anopheles gambiae. Science. 2002;298(5591):176-8. Lyu Z, Li Z, Cheng J, Wang C, Chen J, Lin T. Suppression of Gene Juvenile Hormone Diol Kinase Delays Pupation in Heortia vitessoides Moore. Insects. 2019;10(9). Thomas DD, Donnelly CA, Wood RJ, Alphey LS. Insect population control using a dominant, repressible, lethal genetic system. Science. 2000;287(5462):2474-6. Alphey L, Andreasen M. Dominant lethality and insect population control. Mol Biochem Parasitol. 2002;121(2):173-8. Tables Table 1 Proportion of transgenic mosquitoes expressing the mBanana fluorescent protein after 24, 25 and 26 generations of selection. Only the M2i line reached homozygosity. Line Generation mBanana Positive mBanana Negative Total Proportion mBanana Positive M1f 24 174 54 228 76% 25 194 77 268 74% 26 223 95 318 70% M2i 24 235 0 235 100% 25 264 0 264 100% 26 323 0 323 100% F2c 24 197 60 257 77% 25 173 66 239 72% 26 283 78 361 78% Additional Declarations Competing interest reported. E.I., T.V.P, G.J. and S.L.H. are salaried employees of Sanaria Inc., the developer and owner of PfSPZ vaccines, and A.E.G. and P.F.B. were salaried employees of Sanaria Inc. when the work was performed. S.L.H. has a financial interest in Sanaria Inc. No other authors have competing interests. Cite Share Download PDF Status: Published Journal Publication published 28 Oct, 2025 Read the published version in Parasites & Vectors → Version 1 posted Editorial decision: Revision requested 24 Apr, 2025 Reviews received at journal 24 Apr, 2025 Reviewers agreed at journal 02 Apr, 2025 Reviewers invited by journal 28 Mar, 2025 Editor assigned by journal 26 Mar, 2025 Submission checks completed at journal 26 Mar, 2025 First submitted to journal 20 Mar, 2025 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-6270709","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":440021398,"identity":"6a9c4a9c-c367-488c-b0b7-4f27ee0ac156","order_by":0,"name":"Ehud Inbar","email":"","orcid":"","institution":"Sanaria Inc","correspondingAuthor":false,"prefix":"","firstName":"Ehud","middleName":"","lastName":"Inbar","suffix":""},{"id":440021399,"identity":"a8bb35d6-df3d-4582-9d06-60ae64f02aac","order_by":1,"name":"Ishaan Samantray","email":"","orcid":"","institution":"Sanaria Inc","correspondingAuthor":false,"prefix":"","firstName":"Ishaan","middleName":"","lastName":"Samantray","suffix":""},{"id":440021400,"identity":"e2de4c2c-4689-4ac5-b402-c370e6d5ac9a","order_by":2,"name":"Robert T. Alford","email":"","orcid":"","institution":"University of Maryland","correspondingAuthor":false,"prefix":"","firstName":"Robert","middleName":"T.","lastName":"Alford","suffix":""},{"id":440021401,"identity":"35e4a60f-45b1-416b-b36b-fc552fd08a63","order_by":3,"name":"Robert A. Harrell","email":"","orcid":"","institution":"University of Maryland","correspondingAuthor":false,"prefix":"","firstName":"Robert","middleName":"A.","lastName":"Harrell","suffix":""},{"id":440021402,"identity":"435a195d-0cd2-4008-8127-d6e61161e78d","order_by":4,"name":"Grace Jennings","email":"","orcid":"","institution":"Sanaria Inc","correspondingAuthor":false,"prefix":"","firstName":"Grace","middleName":"","lastName":"Jennings","suffix":""},{"id":440021403,"identity":"d5bf25bd-8d0b-4bfb-8f39-86957214f476","order_by":5,"name":"Tales V. Pascini","email":"","orcid":"","institution":"Sanaria Inc","correspondingAuthor":false,"prefix":"","firstName":"Tales","middleName":"V.","lastName":"Pascini","suffix":""},{"id":440021404,"identity":"04c1bce1-066a-4619-ad30-edd7553d0d78","order_by":6,"name":"Tint T. Wai","email":"","orcid":"","institution":"Sanaria Inc","correspondingAuthor":false,"prefix":"","firstName":"Tint","middleName":"T.","lastName":"Wai","suffix":""},{"id":440021405,"identity":"9a8ec0f4-e33a-400e-9786-f169dbdc350a","order_by":7,"name":"Abraham Eappen","email":"","orcid":"","institution":"Sanaria Inc","correspondingAuthor":false,"prefix":"","firstName":"Abraham","middleName":"","lastName":"Eappen","suffix":""},{"id":440021406,"identity":"e7a67782-c135-4677-b66e-41150bb05729","order_by":8,"name":"Stephen L. Hoffman","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA4UlEQVRIiWNgGAWjYDACdh4GhgobEKMBzOchrIUZqOZMGkjtAZK1SCQQ6S75Zt6DDw4kbJM3l3z+8HNBzT0Z/gbmh49u4NFicJgv2eBAwm3DnbNzjKVnHCvmkTjAZmycg08LM4+Z9Mcftxk33M5hkOZhS+BhOMDDJo1Pi3wzj5kE0Bb7DTePP/7N8y+BR56QFobDEC2JG24wmEnztiXwGBDSYnCYxxjkl+QNZ3LMrHn7EngMDxPwi3x7jyEwxG7bbjh+/PFtnm8J9nLHmx8+xuswTMBMmvJRMApGwSgYBVgAAJQTSvTR0CLaAAAAAElFTkSuQmCC","orcid":"","institution":"Sanaria Inc","correspondingAuthor":true,"prefix":"","firstName":"Stephen","middleName":"L.","lastName":"Hoffman","suffix":""},{"id":440021407,"identity":"4d0388e2-7c71-4338-b4e9-9af6c6c88fc3","order_by":9,"name":"Peter F. Billingsley","email":"","orcid":"","institution":"The Vital Narrative","correspondingAuthor":false,"prefix":"","firstName":"Peter","middleName":"F.","lastName":"Billingsley","suffix":""}],"badges":[],"createdAt":"2025-03-20 14:53:14","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-6270709/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-6270709/v1","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.1186/s13071-025-07003-7","type":"published","date":"2025-10-28T15:57:55+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":80742336,"identity":"47fc42de-f58e-46c4-a299-296664fbaeca","added_by":"auto","created_at":"2025-04-16 14:39:12","extension":"jpg","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":31571,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eSchematic representation of the driver line construct\u003c/strong\u003e. The rtTA ORF was designed to be expressed under the vasa or bZip promoters. The mBanana is expressed under the 3Xp3 promoter. The SV40 3’UTR is used as transcription termination for both genes. The cassette was placed between 2 \u003cem\u003epiggyBac\u003c/em\u003e transposon elements (yellow)\u003c/p\u003e","description":"","filename":"Fig1.jpg","url":"https://assets-eu.researchsquare.com/files/rs-6270709/v1/e1b948c49277a16fc262c5e4.jpg"},{"id":80743773,"identity":"183e1ea7-180f-498e-8399-5541e7d32bdd","added_by":"auto","created_at":"2025-04-16 14:55:12","extension":"jpg","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":102744,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003ertTA mRNA abundance under bZip and vasa early embryonic promoters. \u003c/strong\u003e(a) Quantitative RT-PCR done on cDNAs produced from RNAs, extracted from individual female adult mosquitoes expressing rtTA using the bZip or vasa promoters, following egg laying. The abundances are relative to a female mosquito from bZip-rtTA M1-2 line. (b) qRT-PCR done on cDNA from pools of eggs laid by 10 females from each group. The results represent the mean mRNA abundances, relative to bZip-rtTA M1-2 line ±SD, n=3. The data were analyzed by one-way ANOVA, * p≤0.05. In both qRT-PCR reactions the ribosomal S7 protein gene was used as the house keeping gene.\u003c/p\u003e","description":"","filename":"Fig2.jpg","url":"https://assets-eu.researchsquare.com/files/rs-6270709/v1/c46469766230ea7d46d0d953.jpg"},{"id":80742341,"identity":"4700a40f-4755-430d-ac67-bede97c6f1e8","added_by":"auto","created_at":"2025-04-16 14:39:12","extension":"jpg","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":214736,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eDiagnostic PCR to identify the zygosity status of the insertion in M1f (a), M2i (b) and F2c (c) driver lines. \u003c/strong\u003ePCR was done on genomic DNA from 3 individual mosquitoes (a-c) from all 3 lines, collected at G7. At G24, mosquitoes (a-c) were collected for M1f and F2c and 6 were collected for M2i (a-f) . Genomic DNA from wt. \u003cem\u003eA. stephensi\u003c/em\u003e female mosquitoes was used as a negative control and water was used as a no template control (NTC). The expected PCR products for the M1F insertion and WT alleles were 7560 and 354 bp, respectively. For M2i the products of the insertion and WT alleles were 7534 and 328, respectively. The expected PCR product for the F2c insertion and WT alleles were 7636 and 430 bp, respectively. Black arrows indicate the position of the PCR products on the gel. Homozygous mosquitoes’ labels are bolded. Homozygous mosquitoes were found only in M2i.\u003c/p\u003e","description":"","filename":"Fig3.jpg","url":"https://assets-eu.researchsquare.com/files/rs-6270709/v1/a32a9bdeb62c6bb382db799f.jpg"},{"id":80742342,"identity":"7a468280-2246-48f3-870b-ed5463431714","added_by":"auto","created_at":"2025-04-16 14:39:12","extension":"jpg","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":114073,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eFecundity in WT and driver line mosquitoes. \u003c/strong\u003e(a) The number of eggs laid per individual female in \u003cem\u003eDrosophila\u003c/em\u003e tubes in experiment #1. (b) The percentage of eggs hatching in experiment #1 was determined by counting the number of larvae in the \u003cem\u003eDrosophila\u003c/em\u003e tubes one day after egg laying. In both panels the results are reported as the geometric means, n=34 for F2c and n=35 for WT, M1f, and M2i lines. In panel B, some values were zero. Whenever a value was 0, it was arbitrarily assigned a value of 1 to allow calculation of the geometric means. (c) The number of eggs laid per individual female in \u003cem\u003eDrosophila\u003c/em\u003e tubes in experiment #2. (d) The percentage of eggs hatching in experiment #2.\u003c/p\u003e","description":"","filename":"Fig4.jpg","url":"https://assets-eu.researchsquare.com/files/rs-6270709/v1/886141fe9bcc44ab6576a805.jpg"},{"id":95039982,"identity":"4b869e14-4675-4abc-803b-e8a3a933d4f6","added_by":"auto","created_at":"2025-11-03 16:06:54","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":1383027,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-6270709/v1/e683fa19-a0a2-4eb4-9afd-5686255829ba.pdf"}],"financialInterests":"Competing interest reported. E.I., T.V.P, G.J. and S.L.H. are salaried employees of Sanaria Inc., the developer and owner of PfSPZ vaccines, and A.E.G. and P.F.B. were salaried employees of Sanaria Inc. when the work was performed. S.L.H. has a financial interest in Sanaria Inc. No other authors have competing interests.","formattedTitle":"\u003cp\u003eSuccessful insertion and expression of a tetracycline transactivator in Anopheles stephensi associated with increased egg production and decreased hatching rate\u003c/p\u003e","fulltext":[{"header":"Background","content":"\u003cp\u003eVector-borne diseases have a devastating impact worldwide, transmitting viruses, bacteria and parasites which account for 17% of all infectious diseases with more than 700,000 death annually (\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e). Malaria is caused by \u003cem\u003ePlasmodium\u003c/em\u003e parasites which are transmitted by anopheline mosquitoes. In 2023, malaria caused 263\u0026nbsp;million illnesses and 597,000 deaths, mainly in young children (\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e). The dengue virus is transmitted by \u003cem\u003eAedes\u003c/em\u003e mosquitoes which poses a risk for roughly 4\u0026nbsp;billion people in 132 countries with annual mortality rate of 40,000 individuals (\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eSanaria\u0026rsquo;s \u003cem\u003ePlasmodium falciparum\u003c/em\u003e (Pf) sporozoites (SPZ) products are composed of live, aseptic, purified cryopreserved PfSPZ (\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e). More than 3,500 individuals have received more than 9,700 doses of PfSPZ products in 44 clinical trials in 14 countries in North America, Europe, Africa, and Asia (\u003cspan additionalcitationids=\"CR4 CR5 CR6 CR7 CR8 CR9 CR10 CR11 CR12 CR13 CR14 CR15 CR16 CR17 CR18 CR19 CR20 CR21 CR22 CR23 CR24 CR25 CR26 CR27 CR28 CR29 CR30\" citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e). Sanaria\u0026reg; PfSPZ vaccines are safe and well tolerated and have achieved 100% efficacy against heterologous controlled human malaria infection at 12 weeks after last dose of vaccine (\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e), sustained protection for at least two years against field transmitted malaria in Africa, including 57% protection against Pf infection for two years with no boosting in Mali (\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e), and protection for at least 6 months against highly variant Pf parasites in Papua (Indonesian West New Guinea) (\u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e). In 2025, clinical trials will begin of Sanaria\u0026rsquo;s 3rd generation vaccine, genetically attenuated PfSPZ-LARC2 Vaccine (\u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e). Recent research conducted in the Netherlands has demonstrated that a genetically attenuated vaccine strain with just a single deletion of the mei2 gene (GA2) exhibits a vaccine efficacy of approximately 90% and is well-tolerated (\u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e, \u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e). Given that PfSPZ-LARC2 is a double knockout vaccine strain, with deletions in both mei2 and LINUP, we anticipate a similar or potentially greater protective efficacy, possibly achievable with just one dose.\u003c/p\u003e \u003cp\u003eAll PfSPZ products are currently produced in aseptic \u003cem\u003eAnopheles stephensi\u003c/em\u003e mosquitoes. Major drivers of the cost of vaccine are the incubator space and the personnel required for production and management of aseptic \u003cem\u003eA. stephensi\u003c/em\u003e. Only female mosquitoes carry the PfSPZ used in PfSPZ vaccines. If males could be eliminated from the manufacturing process, we would be able to produce double the numbers of PfSPZ in the same space and with the same personnel, thereby significantly reducing the cost of goods.\u003c/p\u003e \u003cp\u003eThe first step in creating \u0026ldquo;female only\u0026rdquo; \u003cem\u003eAn. stephensi\u003c/em\u003e mosquitoes was to generate a driver line for conditional expression. To do this we used a tetracycline-controlled transcription mechanism, one that is central to tetracycline resistance of gram-negative bacteria (\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e), and has been adapted to conditionally express genes in different eukaryotic systems, including mammals and insects (\u003cspan additionalcitationids=\"CR39 CR40 CR41\" citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR42\" class=\"CitationRef\"\u003e42\u003c/span\u003e). In this system, a gene of interest is regulated by the tetracycline response element (TRE), which consists of multiple units of the tetracycline operator (TetO). Transcription is initiated only when the tetracycline transactivator (tTA), a DNA-binding protein, binds to the TRE (\u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e, \u003cspan citationid=\"CR42\" class=\"CitationRef\"\u003e42\u003c/span\u003e, \u003cspan citationid=\"CR43\" class=\"CitationRef\"\u003e43\u003c/span\u003e). There are two main mechanistic adaptations of this system, Tet-On and Tet-off. In the Tet-off system, the tTA is bound to tetracycline or its derivative doxycycline to prevent binding of the tTA to the TRE; when the drug is removed, the tTA binds to the TRE to initiate transcription of the gene of interest. Conversely, in the Tet-on system, the tTA is modified to a reverse tetracycline transactivator (rtTA) which binds to the TRE in the presence of doxycycline to initiate transcription. When the drug is removed the rtTA is released from the TRE and transcription stops (\u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e, \u003cspan citationid=\"CR42\" class=\"CitationRef\"\u003e42\u003c/span\u003e, \u003cspan citationid=\"CR43\" class=\"CitationRef\"\u003e43\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eThe Tet system has been used in vector control approaches to decrease populations of various disease-transmitting vectors, using Release of Insects carrying a Dominant Lethal gene (RIDL). RIDL is an improved version of the classical release of sterile insect technique (SIT) (\u003cspan citationid=\"CR44\" class=\"CitationRef\"\u003e44\u003c/span\u003e). Male \u003cem\u003eAedes aegypti\u003c/em\u003e mosquitoes carrying lethal genes are released to mate with wild-type females and transmit the lethal genes to future generations. In the absence of tetracycline or doxycycline in the field, lethal genes are induced and the mosquitoes are killed, usually at the early larval stage (\u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e, \u003cspan citationid=\"CR41\" class=\"CitationRef\"\u003e41\u003c/span\u003e, \u003cspan additionalcitationids=\"CR46 CR47 CR48\" citationid=\"CR45\" class=\"CitationRef\"\u003e45\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR49\" class=\"CitationRef\"\u003e49\u003c/span\u003e). Currently, there is an extensive effort to use RIDL to reduce populations of \u003cem\u003eAe. aegypti\u003c/em\u003e to fight the spread of arboviruses including Zika, Yellow Fever and Dengue (\u003cspan citationid=\"CR47\" class=\"CitationRef\"\u003e47\u003c/span\u003e, \u003cspan citationid=\"CR50\" class=\"CitationRef\"\u003e50\u003c/span\u003e, \u003cspan citationid=\"CR51\" class=\"CitationRef\"\u003e51\u003c/span\u003e).\u003cdiv class=\"BlockQuote\"\u003e\u003cp\u003eOur plan is to use the tetracycline conditional expression system to drive expression of a male lethal gene thereby creating \u0026ldquo;female-only\u0026rdquo; aseptic mosquitoes for PfSPZ production. Here we report our successful generation of a homozygous driver line of mosquitoes expressing rtTA (Tet-On) to be used to drive expression of a male lethal gene.\u003c/p\u003e\u003c/div\u003e\u003c/p\u003e"},{"header":"Methods","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003eMosquito rearing\u003c/h2\u003e \u003cp\u003e \u003cem\u003eAnopheles stephensi\u003c/em\u003e SDA500 were reared at the Insect transformation facility (ITF) of the University of Maryland\u0026rsquo;s institute for Bioscience and Biotechnology Research (IBBR) in Rockville, MD, at 28\u003csup\u003eo\u003c/sup\u003eC, 75% humidity and 12h:12h light:dark cycle with 30-minute dawn and dusk periods.\u003c/p\u003e \u003c/div\u003e\n\u003ch3\u003eConstruction of driver lines: construction of vasa-rtTA in PiggyBac vector and embryo injections\u003c/h3\u003e\n\u003cp\u003eThe reverse tetracycline transactivator (rtTA) gene, fused to VP16 transcription activation domain was synthesized by GeneScript company (Piscataway NJ, USA). The vasa promoter was amplified from \u003cem\u003eAn. stephensi\u003c/em\u003e genomic DNA. We assembled vasa-rtTA-SV40 using NEBuilder\u0026reg; HiFi DNA Assembly Cloning Kit (NEB #E5520S). The entire construct was ligated into the \u003cem\u003epiggyBac\u003c/em\u003e transposon vector containing mBanana gene under the 3Xp3 promoter (\u003cspan citationid=\"CR52\" class=\"CitationRef\"\u003e52\u003c/span\u003e) for easy identification of transgenic An. \u003cem\u003estephensi\u003c/em\u003e. The injections were done as described previously (\u003cspan citationid=\"CR53\" class=\"CitationRef\"\u003e53\u003c/span\u003e, \u003cspan citationid=\"CR54\" class=\"CitationRef\"\u003e54\u003c/span\u003e). Briefly, Preblastodermal embryos were injected, 40\u0026ndash;60 minutes post embryo collection, with an injection mix consisting of 150 ng/\u0026micro;L of \u003cem\u003epiggyBac\u003c/em\u003e vector and 193 ng/\u0026micro;L of \u003cem\u003epiggyBac\u003c/em\u003e transposase mRNA in halocarbon oil, as described (\u003cspan citationid=\"CR54\" class=\"CitationRef\"\u003e54\u003c/span\u003e)\u003c/p\u003e\n\u003ch3\u003eDNA work, Splinkerette mapping and RNA work\u003c/h3\u003e\n\u003cp\u003eDNA was extracted from individual adult mosquitoes using DNeasy (Qiagen #69504) as described (\u003cspan citationid=\"CR55\" class=\"CitationRef\"\u003e55\u003c/span\u003e). Splinkerette mapping of transposable elements was done as described for \u003cem\u003eD. melanogaster\u003c/em\u003e (\u003cspan citationid=\"CR56\" class=\"CitationRef\"\u003e56\u003c/span\u003e). Briefly, genomic DNA was digested by BstYI (NEB # R0523S) and the fragments ligated to a Splinkerette element on 5\u0026rsquo; and 3\u0026rsquo; ends. Fragments containing the insertions were amplified by two cycles of PCR, using the primers from both ends of the \u003cem\u003ePiggyBac\u003c/em\u003e insertions to the Splinkerette at the ends of the fragments, as designed [60]. The PCR amplicons were sent for Sanger sequencing and the sequences sequences were aligned against the An. \u003cem\u003estephensi\u003c/em\u003e SDA500 genome at VEuPathDB, VectorBase (\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://vectorbase.org/vectorbase/app/\u003c/span\u003e\u003cspan address=\"https://vectorbase.org/vectorbase/app/\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e). RNA was extracted as described (\u003cspan citationid=\"CR55\" class=\"CitationRef\"\u003e55\u003c/span\u003e), using Qiagen RNeasy mini kit (Qiagen #74106) according to the manufacturer instructions. Complimentary (c)DNAs were synthesized using the High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher # 4368814) on extracted RNAs. Real-time PCR reactions were done on cDNAs using SensiFAST\u0026trade; Real-Time PCR Kits (Bioline # BIO-82005). The ribosomal protein S7 was used as a house keeping control (\u003cspan citationid=\"CR55\" class=\"CitationRef\"\u003e55\u003c/span\u003e).\u003c/p\u003e\n\u003ch3\u003eAssessment of fecundity\u003c/h3\u003e\n\u003cp\u003eThree days after blood feeding, females were placed individually in plastic \u003cem\u003eDrosophila\u003c/em\u003e cylinders containing water and sealed with cotton balls (\u003cspan citationid=\"CR55\" class=\"CitationRef\"\u003e55\u003c/span\u003e). The mosquitoes were incubated overnight at \u0026gt;\u0026thinsp;70% humidity, 28\u003csup\u003eo\u003c/sup\u003eC. The next day, the mosquitoes were removed from the tubes and the eggs were counted. The larvae were counted in the tubes 1\u0026ndash;2 days after egg laying. The larvae hatching rate was determined as the percent larvae per the total number of eggs in each tube. Data were analyzed using GraphPad Prism version 10.2.1 for Windows.\u003c/p\u003e"},{"header":"Results","content":"\u003cdiv id=\"Sec8\" class=\"Section2\"\u003e \u003ch2\u003eGeneration of An. stephensi driver line, expressing rtTA under the vasa promoter\u003c/h2\u003e \u003cp\u003eWe constructed a driver line in which the reverse tetracycline transactivator (rtTA, Tet-On) was expressed under the early embryonic promoter, bZip. Assessments of rtTA transcript abundance by quantitative (q) RT-PCR revealed very low mRNA levels of rtTA in eggs, ovaries and adults (data not shown). We therefore replaced the bZip promoter with the early embryonic vasa promoter. For this vasa-rtTA construct, an mBanana fluorescent marker, driven by the 3XP3 promoter was placed in the reverse orientation to the vasa-rtTA expression cassette. The construct was placed into a \u003cem\u003epiggybac\u003c/em\u003e vector (\u003cspan citationid=\"CR52\" class=\"CitationRef\"\u003e52\u003c/span\u003e) between two transposon elements (Fig.\u0026nbsp;1), then mixed with a transposase-expressing vector (\u003cspan citationid=\"CR54\" class=\"CitationRef\"\u003e54\u003c/span\u003e) and injected into \u003cem\u003eAn\u003c/em\u003e. \u003cem\u003estephensi\u003c/em\u003e eggs at the early embryonic stage. Out of 854 eggs injected, 45 hatched and 29 (14 males and 15 females) survived to adults. Males (M) and females (F) were sorted and grouped into cages and crossed with the opposite sex of wild type mosquitoes. Larvae of the subsequent generation (G\u003csub\u003e1\u003c/sub\u003e), were screened using a fluorescent microscope and transgenic larvae expressing mBanana were collected. From the M group, 114 G\u003csub\u003e1\u003c/sub\u003e larvae were mBanana-positive, of which 43 males and 39 females survived to adults. Fifty-six mBanana-positive larvae, 27 males and 29 females, were obtained from the F group, all surviving to adults. To avoid mixing of genotypes, we separated transgenic lines by collecting eggs from 20 individual G\u003csub\u003e1\u003c/sub\u003e M-group females and 14 individual G\u003csub\u003e1\u003c/sub\u003e F-group females. After oviposition, RNA was extracted from the G\u003csub\u003e1\u003c/sub\u003e females and qRT-PCR used to assess rtTA mRNA abundance (data not shown).\u003c/p\u003e \u003c/div\u003e\n\u003ch3\u003eThe rtTA transcription levels under early embryonic vasa and bZip promoters\u003c/h3\u003e\n\u003cp\u003eWe selected 4 different lines originating from G\u003csub\u003e1\u003c/sub\u003e female mosquitoes (2 from the M-group and 2 from the F-group) with the highest abundance of rtTA mRNA. We compared the rtTA mRNA levels of the 4 mosquito lines (M1F, M2i, F2C and F2e) to that of 3 transgenic lines we had previously created that express rtTA under the early embryonic bZip promoter, M1-2, M3-2 and M3-3. The rtTA mRNA level in bZip-rtTA M1-2 line was used as a reference. The rtTA mRNA abundance in all three bZip-rtTA lines were comparable (Fig.\u0026nbsp;2a). In the vasa-rtTA lines mRNA abundance was 1,538-, 2,326-, 562- and 380-fold higher in M1f, M2i, F2c and F2e lines, respectively than in reference bZip-rtTA line (M1-2) (Fig.\u0026nbsp;2a).\u003c/p\u003e \u003cp\u003eLine F2e was lost due to an insectary failure. We crossed the transgenic vasa-rtTA M1f, F2c and M2i lines to WT through 4 generations to expand the lines and reduce the number of inserts. Since the vasa promoter can drive expression in the early stages of embryonic development (\u003cspan citationid=\"CR57\" class=\"CitationRef\"\u003e57\u003c/span\u003e), we assessed rtTA transcript abundance in embryos 1 h after oviposition (Fig.\u0026nbsp;2b). The mean rtTA mRNA abundance was 1714-, 2,813- and 405-fold higher than in eggs from the bZip-rtTA line M1-2, in the eggs from the M1f, M2i and M1-2 lines respectively. As seen in the adult mosquitoes, the rtTA mRNA abundance in M2i was higher than in all other lines, and significantly higher compared to F2c embryos (Fig.\u0026nbsp;2a and b).\u003c/p\u003e\n\u003ch3\u003eMapping the transposon-based insertions of the driver construct and generation of homozygous mosquitoes\u003c/h3\u003e\n\u003cp\u003eFrom G\u003csub\u003e6\u003c/sub\u003e onwards, the lines were in-crossed to obtain homozygosity of the insertion. We collected genomic (g)DNA at G\u003csub\u003e7\u003c/sub\u003e and used it to identify the genomic locus of the transposon-based insertion in each line using the Splinkerette PCR protocol (see materials and methods). The sequences were aligned against the \u003cem\u003eAn\u003c/em\u003e. \u003cem\u003estephensi\u003c/em\u003e genome in VectorBase. In the M1F line, the vasa construct was inserted into supercontig KB664888, position 665,462, which is within an exon in the open reading frame (ORF) of an \u0026ldquo;Era G-protein-like\u0026rdquo; (ASTE010067) coding sequence. In the F2c line the insertion was in supercontig KB665088, position 785,341, which is not in any known ORF. In the M2i line, the vasa construct was inserted into supercontig KB665343 position, 382,729, which is within the last intron of a putative juvenile hormone diol kinase gene (ASTE000415).\u003c/p\u003e \u003cp\u003eWe continued to in-cross the 3 lines through subsequent generations while monitoring the proportion of mBanana expressing larvae in each generation as an indication of their progression toward homozygosity. In the M2i line almost all the larvae were transgenic after G\u003csub\u003e17\u003c/sub\u003e, while in the F2c and M1f lines only about two thirds of the larvae expressed mBanana. We therefore carefully tracked the proportion of mBanana-positive larvae through generations 24, 25 and 26 (Tables\u0026nbsp;1). All M2i larvae expressed mBanana in generations 24\u0026ndash;26. Only 76%, 74% and 80% of M1f larvae and 77%, 72% and 78% of F2c larvae expressed mBanana in generations 24, 25 and 26, respectively. Based on the positions of the inserts in each line, we designed PCR primers flanking the insertions to determine the zygosity level in each line (Fig.\u0026nbsp;3). All three M1f and F2c tested mosquitoes were heterozygous at G\u003csub\u003e7\u003c/sub\u003e and continued to be heterozygous at G\u003csub\u003e24\u003c/sub\u003e. Two of 3 mosquitoes in the M2i line were homozygous at G\u003csub\u003e7\u003c/sub\u003e (b and c), and 4 of 6 mosquitoes (a, b, d and f) were homozygous at G\u003csub\u003e24\u003c/sub\u003e (Fig.\u0026nbsp;3).\u003c/p\u003e \u003cdiv id=\"Sec11\" class=\"Section2\"\u003e \u003ch2\u003eAssessment of potential insertion-related fitness cost\u003c/h2\u003e \u003cp\u003eTo assess the effect of the rtTA expression on fitness, we compared the fecundity in all 3 lines with that of WT \u003cem\u003eAn\u003c/em\u003e. \u003cem\u003estephensi\u003c/em\u003e. From each line, eggs from up to 100 individual females were counted and the proportion of eggs hatching determined. From the WT line, 83% laid eggs. Likewise, 86% and 84% of the females laid eggs in the M2i and F2c groups, respectively. Only 59 out of 86 (68%) M1f females laid eggs. The geometric mean (GM) number of eggs laid per individual female in the WT line was 145, (95% CI\u0026thinsp;=\u0026thinsp;133\u0026ndash;159). In the M1f line the number of eggs/ female was slightly but not significantly lower [GM\u0026thinsp;=\u0026thinsp;123, 95% CI\u0026thinsp;=\u0026thinsp;106\u0026ndash;143), while the numbers of eggs laid by M2i (GM\u0026thinsp;=\u0026thinsp;181, 95% CI\u0026thinsp;=\u0026thinsp;169\u0026ndash;195) and F2c (GM\u0026thinsp;=\u0026thinsp;190, 95% CI\u0026thinsp;=\u0026thinsp;175\u0026ndash;207) females were significantly higher than those of WT and the M1f line (Fig.\u0026nbsp;4a). The GM of the percentage larvae hatching in WT was 76% (95% CI\u0026thinsp;=\u0026thinsp;65\u0026ndash;88). Hatching rates were significantly lower in all three driver lines, 38% (95% CI\u0026thinsp;=\u0026thinsp;45\u0026ndash;63) in M1f, 42% (95% CI\u0026thinsp;=\u0026thinsp;30\u0026ndash;59) in M2i, and 53% (95% CI\u0026thinsp;=\u0026thinsp;45\u0026ndash;62) in F2c (Fig.\u0026nbsp;4b). In the following generation, the number of eggs laid per M2i female (GM\u0026thinsp;=\u0026thinsp;167, 95% CI\u0026thinsp;=\u0026thinsp;154\u0026ndash;181) was again higher than WT females (GM\u0026thinsp;=\u0026thinsp;149, 95% CI\u0026thinsp;=\u0026thinsp;139\u0026ndash;159) (Fig.\u0026nbsp;4c), and the hatching rate in M2i (GM\u0026thinsp;=\u0026thinsp;55%, 95% CI\u0026thinsp;=\u0026thinsp;44\u0026ndash;70) was significantly lower compared to that of WT (GM\u0026thinsp;=\u0026thinsp;81, 95% CI\u0026thinsp;=\u0026thinsp;77\u0026ndash;85) (Fig.\u0026nbsp;4d), confirming the pervious observation (Fig.\u0026nbsp;4 a\u0026amp;b).\u003c/p\u003e \u003c/div\u003e"},{"header":"Discussion","content":"\u003cp\u003eOur long -term goal is to establish a system for conditionally expressing foreign genes in \u003cem\u003eAn\u003c/em\u003e. \u003cem\u003estephensi\u003c/em\u003e. Our medium-term goal is to use this system to conditionally express a lethal gene in male mosquitoes to increase the efficiency of our manufacturing process. In the present study we created the driver line for the conditional expression that can be crossed with the effector line to generate mosquitoes with the desired phenotype.\u003c/p\u003e \u003cp\u003eWe evaluated two promoters for driving expression of rtTA. For unknown reasons, transcription of rtTA was minimal under bZip. This finding is consistent with a previous study done in \u003cem\u003eAe. aegypti\u003c/em\u003e, which showed that while the bZip promoter effectively drove strong transcription of the mNG fluorescent marker, it failed to initiate transcription of tTA (\u003cspan citationid=\"CR58\" class=\"CitationRef\"\u003e58\u003c/span\u003e). In contrast, the vasa promoter facilitated high levels of rtTA expression. The vasa promoter has been shown previously to drive endogenous vasa gene expression as well as exogenous eGFP expression in ovaries, testis and 1\u0026ndash;2 h post-oviposition embryos of An. \u003cem\u003egambiae\u003c/em\u003e (\u003cspan citationid=\"CR57\" class=\"CitationRef\"\u003e57\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eWe were unable to obtain homozygosity in lines M1f and F2c, while in the 3rd line, M2i, homozygosity was established as early as G\u003csub\u003e7\u003c/sub\u003e. rtTA mRNA expression in M2i was higher than in M1f and F2c, likely due the fact that there was an rtTA encoding gene on both chromosomes, not just one. Thus, it appears that the inability to reach homozygosity in M1f and F2c was not due to rtTA expression but rather to the genomic locus of the insertions.\u003c/p\u003e \u003cp\u003eIn the M1f line the rtTA insertion was within an exon in a coding gene, Era G-protein-like (ASTE010067), a member of a family of G-proteins associated with signal transduction and involved in many aspects of the life cycles in many organisms. One essential, well known function of G-proteins in insects, including Anophelines, is in the sensing of environmental signals through odorant binding proteins and the response of the insects to those signals (\u003cspan citationid=\"CR59\" class=\"CitationRef\"\u003e59\u003c/span\u003e, \u003cspan citationid=\"CR60\" class=\"CitationRef\"\u003e60\u003c/span\u003e). It is therefore highly likely that ASTE010067 is an essential gene, and the mosquitoes cannot tolerate disruption of both of its copies. In F2c, the insertion was at the 3\u0026rsquo; end of supercontig KB665088, in a non-coding region, which may be crucial for mosquito survival.\u003c/p\u003e \u003cp\u003eIn M2i, the insertion was in an intron of a putative juvenile hormone diol kinase gene (ASTE000415). In the moth, \u003cem\u003eHeortia vitessoides\u003c/em\u003e, juvenile hormone diol kinase is involved in hormone recycling and is essential for the development and survival of the moth (\u003cspan citationid=\"CR61\" class=\"CitationRef\"\u003e61\u003c/span\u003e). The ability to obtain homozygosity suggests that the insertion in the intron did not affect the expression and activity of the gene. Four out of 6 G\u003csub\u003e24\u003c/sub\u003e M2i mosquitoes were homozygous for the insertion, indicating that the insertion was still not fixed in the population. It was therefore surprising that by microscope screening, 100% of the larvae were mBanana positive. It is possible that in M2i there are one or more insertions in genes in addition to the putative juvenile hormone diol kinase gene (ASTE000415) that were not detected by the Splinkerette mapping. The fact that all the larvae were positive by microscopy in three consecutive generations (G\u003csub\u003e24\u003c/sub\u003e-G\u003csub\u003e26\u003c/sub\u003e) suggests that at least one of the undetected insertions is already fixed in the population and its position is not in an essential locus in the genome.\u003c/p\u003e \u003cp\u003eThe homozygous line, M2i produced significantly more eggs (24% and 12%) than the WT mosquitoes in two experiments (Fig.\u0026nbsp;4). However, M2i had a significantly lower (45% and 33%) rate of larval hatching in (Fig.\u0026nbsp;4). Thus, the efficiency overall of producing larvae was reduced by about 21%. Since the driver line will next be crossed with an effector line, it remains to be seen whether this reduced hatching rate will impact production of adults in the final product. Expression of tTA has been associated with fitness costs in insects. Overexpression in \u003cem\u003eD. melanogaster\u003c/em\u003e had a toxic effect on early development in heterozygous progeny due to interference in ubiquitination and protein proteolysis as well as transcriptional squelching (\u003cspan citationid=\"CR41\" class=\"CitationRef\"\u003e41\u003c/span\u003e). Thus, it was used later as a lethal gene in RIDL systems in \u003cem\u003eAe. aegypti\u003c/em\u003e and \u003cem\u003eD. melanogaster\u003c/em\u003e (\u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e, \u003cspan citationid=\"CR46\" class=\"CitationRef\"\u003e46\u003c/span\u003e). The lethal effect of tTAV, a codon-optimized version of tTA, on transcription in \u003cem\u003eD. melanogaster\u003c/em\u003e is dependent on the site of the genomic integration. All insertions have negative effects on early development, but each insertion triggers a different transcriptional profile leading to different phenotypes (\u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e). Based on these observations, Oxitec developed transgenic mosquitoes in which females are being killed in the field by overexpressing the tTA in a positive feedback loop (\u003cspan citationid=\"CR46\" class=\"CitationRef\"\u003e46\u003c/span\u003e, \u003cspan citationid=\"CR62\" class=\"CitationRef\"\u003e62\u003c/span\u003e, \u003cspan citationid=\"CR63\" class=\"CitationRef\"\u003e63\u003c/span\u003e). In these mosquitoes, only minimal levels of tTA are being produced when tetracycline is present in the larval diet but when these mosquitoes are released in the field with no tetracycline, the tTA binds to TetO allowing overexpression of the downstream tTA in females, and mortality of subsequent mosquito generations at the early larval stage. Release of these mosquitoes in field studies in the United States and Brazil led to reductions of up to 96% of the mosquito populations (\u003cspan citationid=\"CR47\" class=\"CitationRef\"\u003e47\u003c/span\u003e, \u003cspan citationid=\"CR50\" class=\"CitationRef\"\u003e50\u003c/span\u003e).\u003c/p\u003e"},{"header":"Conclusions","content":"\u003cp\u003eIn summary, we successfully completed the first step in creating \u003cem\u003eAn\u003c/em\u003e. \u003cem\u003estephensi\u003c/em\u003e with a male-lethal allele controlled by a conditional gene expression system. We produced \u003cem\u003eAn\u003c/em\u003e. \u003cem\u003estephensi\u003c/em\u003e homozygous driver line, M2i, that expresses rtTA under the early embryonic vasa promoter. Egg production by m2i was ~\u0026thinsp;18% greater than by WT mosquitoes, and the hatching rate of eggs to larvae\u0026thinsp;~\u0026thinsp;39% lower than in WT mosquitoes. This overall 21% decrease in fecundity is acceptable for moving to the next step which will be to cross the M2i driver line with an effector line carrying a male-lethal gene. In the final product the rtTA transcription factor will bind to the tetracycline responsive element (TRE) in the presence of doxycycline, driving lethal gene expression only in males. Success in step 2 will provide the foundation for crossing the driver line described herein with other lines to conditionally express any target gene in \u003cem\u003eAn\u003c/em\u003e. \u003cem\u003estephensi\u003c/em\u003e.\u003c/p\u003e "},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eEthics approval and consent to participate:\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNot applicable\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConsent for publication:\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNot applicable\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAvailability of data and materials:\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAll data generated or analyzed during this study are included in this published article.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompeting interests\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eE.I., A.E.G., T.V.P, G.J., P.F.B., and S.L.H. are salaried employees of Sanaria Inc., the developer and owner of PfSPZ vaccines, and A.E.G. and P.F.B. were salaried employees of Sanaria Inc. when the work was performed. S.L.H. has a financial interest in Sanaria Inc. No other authors have competing interests.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFundings:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis work was funded by the two NIAID-NIH SBIR grants 1R43AI143077 and 5R43AI174393.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthor Contributions\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eE.I., R.T.A., R.A.H., A.E.G., T.V.P. \u0026nbsp;and G.J. performed the work and contributed to data collection. E.I., A.E.G., R.A.H., S.L.H. and P.F.B., designed the studies and with T. V. P. supervised the project. \u0026nbsp; E.I., T. V. P. R.A.H., P.F.B. and S.L.H. wrote the manuscript. All authors discussed the results and commented on the manuscript.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n \u003cli\u003eVector-borne diseases [Internet]. World Health Organization 2024 [cited 09/26/2024]. Available from: https://www.who.int/news-room/fact-sheets/detail/vector-borne-diseases#:~:text=Vector%\u003cbr\u003e2Dborne%20diseases%20are%20human,spread%20of%20vector%2Dborne%20diseases.\u003c/li\u003e\n \u003cli\u003eHoffman SL, Billingsley PF, James E, Richman A, Loyevsky M, Li T, et al. Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hum Vaccin. 2010;6(1):97-106.\u003c/li\u003e\n \u003cli\u003eSissoko MS, Healy SA, Katile A, Omaswa F, Zaidi I, Gabriel EE, et al. Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial. Lancet Infect Dis. 2017;17(5):498-509.\u003c/li\u003e\n \u003cli\u003eJongo SA, Shekalage SA, Church LWP, Ruben AJ, Schindler T, Zenklusen I, et al. Safety, Immunogenicity, and Protective Efficacy against Controlled Human Malaria Infection of Plasmodium falciparum Sporozoite Vaccine in Tanzanian Adults. Am J Trop Med Hyg. 2018;99(2):338-49.\u003c/li\u003e\n \u003cli\u003eOlotu A, Urbano V, Hamad A, Eka M, Chemba M, Nyakarungu E, et al. Advancing Global Health through Development and Clinical Trials Partnerships: A Randomized, Placebo-Controlled, Double-Blind Assessment of Safety, Tolerability, and Immunogenicity of Plasmodium falciparum Sporozoites Vaccine for Malaria in Healthy Equatoguinean Men. Am J Trop Med Hyg. 2018;98(1):308-18.\u003c/li\u003e\n \u003cli\u003eJongo SA, Church LWP, Mtoro AT, Chakravarty S, Ruben AJ, Swanson PA, et al. Safety and Differential Antibody and T-Cell Responses to the Plasmodium falciparum Sporozoite Malaria Vaccine, PfSPZ Vaccine, by Age in Tanzanian Adults, Adolescents, Children, and Infants. Am J Trop Med Hyg. 2019;100(6):1433-44.\u003c/li\u003e\n \u003cli\u003eRoestenberg M, Walk J, van der Boor SC, Langenberg MCC, Hoogerwerf MA, Janse JJ, et al. A double-blind, placebo-controlled phase 1/2a trial of the genetically attenuated malaria vaccine PfSPZ-GA1. Sci Transl Med. 2020;12(544):eaaz5629.\u003c/li\u003e\n \u003cli\u003eSteinhardt LC, Richie TL, Yego R, Akach D, Hamel MJ, Gutman JR, et al. Safety, tolerability, and immunogenicity of PfSPZ Vaccine administered by direct venous inoculation to infants and young children: findings from an age de-escalation, dose-escalation double-blinded randomized, controlled study in western Kenya. Clin Infect Dis. 2020;71(14):1063-71.\u003c/li\u003e\n \u003cli\u003eJongo SA, Urbano V, Church LWP, Olotu A, Manock SR, Schindler T, et al. Immunogenicity and Protective Efficacy of Radiation-Attenuated and Chemo-Attenuated PfSPZ Vaccines in Equatoguinean Adults. Am J Trop Med Hyg. 2021;104(1):283-93.\u003c/li\u003e\n \u003cli\u003eSissoko MS, Healy SA, Katile A, Zaidi I, Hu Z, Kamate B, et al. Three dose regimen of PfSPZ Vaccine protects adult Malians against\u003cem\u003e\u0026nbsp;Plasmodium falciparum\u003c/em\u003e through an intense transmission season: a randomized, controlled phase I trial. Lancet Infect Dis Nov 18;S1473-3099(21)00332-7. 2021.\u003c/li\u003e\n \u003cli\u003eOneko M, Steinhardt LC, Yego R, Wiegand RE, Swanson PA, Kc N, et al. Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial. Nat Med. 2021;27(9):1636-45.\u003c/li\u003e\n \u003cli\u003eEpstein JE, Tewari K, Lyke KE, Sim BK, Billingsley PF, Laurens MB, et al. Live attenuated malaria vaccine designed to protect through hepatic CD8+T cell immunity. Science. 2011;334(6055):475-80.\u003c/li\u003e\n \u003cli\u003eRoestenberg M, Bijker EM, Sim BK, Billingsley PF, James ER, Bastiaens GJ, et al. Controlled Human Malaria Infections by Intradermal Injection of Cryopreserved \u003cem\u003ePlasmodium falciparum\u0026nbsp;\u003c/em\u003eSporozoites. Am J Trop Med Hyg. 2013;88(1):5-13.\u003c/li\u003e\n \u003cli\u003eSeder RA, Chang LJ, Enama ME, Zephir KL, Sarwar UN, Gordon IJ, et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science. 2013;341(6152):1359-65.\u003c/li\u003e\n \u003cli\u003eSheehy SH, Spencer AJ, Douglas AD, Sim BK, Longley RJ, Edwards NJ, et al. Optimising Controlled Human Malaria Infection Studies Using Cryopreserved Parasites Administered by Needle and Syringe. PLoS One. 2013;8(6):e65960.\u003c/li\u003e\n \u003cli\u003eShekalaghe S, Rutaihwa M, Billingsley PF, Chemba M, Daubenberger CA, James ER, et al. Controlled human malaria infection of Tanzanians by intradermal injection of aseptic, purified, cryopreserved \u003cem\u003ePlasmodium falciparum\u003c/em\u003e sporozoites. Am J Trop Med Hyg. 2014;91(3):471-80.\u003c/li\u003e\n \u003cli\u003eHodgson SH, Juma EA, Salim A, Magiri C, Kimani D, Njenga D, et al. Evaluating Controlled Human Malaria Infection in Kenyan Adults with Varying Degrees of Prior Exposure to Plasmodium falciparum using sporozoites administered by intramuscular injection. Frontiers in Microbiology. 2014;5:686.\u003c/li\u003e\n \u003cli\u003eBastiaens GJ, van Meer MP, Scholzen A, Obiero JM, Vatanshenassan M, van Grinsven T, et al. Safety, Immunogenicity, and Protective Efficacy of Intradermal Immunization with Aseptic, Purified, Cryopreserved Plasmodium falciparum Sporozoites in Volunteers Under Chloroquine Prophylaxis: A Randomized Controlled Trial. Am J Trop Med Hyg. 2016;94(3):663-73.\u003c/li\u003e\n \u003cli\u003eGomez-Perez GP, Legarda A, Munoz J, Sim BK, Ballester MR, Dobano C, et al. Controlled human malaria infection by intramuscular and direct venous inoculation of cryopreserved Plasmodium falciparum sporozoites in malaria-naive volunteers: effect of injection volume and dose on infectivity rates. Malar J. 2015;14:306.\u003c/li\u003e\n \u003cli\u003eLyke KE, Laurens MB, Strauss K, Adams M, Billingsley PF, James E, et al. Optimizing Intradermal Administration of Cryopreserved Plasmodium falciparum Sporozoites in Controlled Human Malaria Infection. Am J Trop Med Hyg. 2015;93(6):1274-84.\u003c/li\u003e\n \u003cli\u003eMordm\u0026uuml;ller B, Supan C, Sim KL, G\u0026oacute;mez-P\u0026eacute;rez GP, Ospina Salazar CL, Held J, et al. Direct venous inoculation of \u003cem\u003ePlasmodium falciparum\u003c/em\u003e sporozoites for controlled human malaria infection: a dose-finding trial in two centres. Malar J. 2015;14:117.\u003c/li\u003e\n \u003cli\u003eIshizuka AS, Lyke KE, DeZure A, Berry AA, Richie TL, Mendoza FH, et al. Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. Nat Med. 2016;22(6):614-23.\u003c/li\u003e\n \u003cli\u003eEpstein JE, Paolino KM, Richie TL, Sedegah M, Singer A, Ruben AJ, et al. Protection against Plasmodium falciparum malaria by PfSPZ Vaccine. JCI Insight. 2017;2(1):e89154.\u003c/li\u003e\n \u003cli\u003eMordmuller B, Surat G, Lagler H, Chakravarty S, Ishizuka AS, Lalremruata A, et al. Sterile protection against human malaria by chemoattenuated PfSPZ vaccine. Nature. 2017;542(7642):445-9.\u003c/li\u003e\n \u003cli\u003eLyke KE, Ishizuka AS, Berry AA, Chakravarty S, DeZure A, Enama ME, et al. Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection. Proc Natl Acad Sci U S A. 2017;114(10):2711-6.\u003c/li\u003e\n \u003cli\u003eLell B, Mordmuller B, Dejon Agobe JC, Honkpehedji J, Zinsou J, Mengue JB, et al. Impact of Sickle Cell Trait and Naturally Acquired Immunity on Uncomplicated Malaria after Controlled Human Malaria Infection in Adults in Gabon. Am J Trop Med Hyg. 2018;98(2):508-15.\u003c/li\u003e\n \u003cli\u003eOneko M, Cherop YR, Sang T, Gutman JR, Wiegand R, Nyang\u0026apos;au EM, et al. Feasibility of direct venous inoculation of the radiation-attenuated Plasmodium falciparum whole sporozoite vaccine in children and infants in Siaya, western Kenya. Vaccine. 2020;38(29):4592-600.\u003c/li\u003e\n \u003cli\u003eLyke KE, Singer A, Berry AA, Reyes S, Chakravarty S, James ER, et al. Multidose Priming and Delayed Boosting Improve PfSPZ Vaccine Efficacy against Heterologous P. falciparum Controlled Human Malaria Infection. Clin Infect Dis. 2021;73(7):e2424-e35.\u003c/li\u003e\n \u003cli\u003eMwakingwe-Omari A, Healy SA, Lane J, Cook DM, Kalhori S, Wyatt C, et al. Two chemoattenuated PfSPZ malaria vaccines induce sterile hepatic immunity. Nature. 2021;595(7866):289-94.\u003c/li\u003e\n \u003cli\u003eMordmuller B, Sulyok Z, Sulyok M, Molnar Z, Lalremruata A, Calle CL, et al. A PfSPZ vaccine immunization regimen equally protective against homologous and heterologous controlled human malaria infection. NPJ Vaccines. 2022;7(1):100.\u003c/li\u003e\n \u003cli\u003eSulyok Z, Fendel R, Eder B, Lorenz FR, Kc N, Karnahl M, et al. Heterologous protection against malaria by a simple chemoattenuated PfSPZ vaccine regimen in a randomized trial. Nat Commun. 2021;12(1):2518.\u003c/li\u003e\n \u003cli\u003eDiawara H, Healy SA, Mwakingwe-Omari A, Issiaka D, Diallo A, Traore S, et al. Safety and efficacy of PfSPZ Vaccine against malaria in healthy adults and women anticipating pregnancy in Mali: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect Dis. 2024;24(12):1366-82.\u003c/li\u003e\n \u003cli\u003eNelwan EJ, Richie hL, Chand K, Indrihutami K, Rachmat A, Chen M-C, et al. Protection of Indonesian soldiers against highly variant Plasmodium falciparum Infection in Papua province, Indonesia, by two PfSPZ vaccines American Society of Tropical Medicine \u0026amp; Hygiene (ASTMH) 2024; New Orleans, LA.\u003c/li\u003e\n \u003cli\u003eGoswami D, Patel H, Betz W, Armstrong J, Camargo N, Patil A, et al. A replication competent Plasmodium falciparum parasite completely attenuated by dual gene deletion. EMBO Mol Med. 2024;16(4):723-54.\u003c/li\u003e\n \u003cli\u003eLamers OA, Franke-Fayard BM, Koopman JPR, Roozen GV, Janse JJ, Chevalley-Maurel SC, et al. Safety and efficacy of immunization with a late-liver-stage attenuated malaria parasite. N Engl J Med. 2024;391(20):1913-23.\u003c/li\u003e\n \u003cli\u003eRoozen GVT, van Schuijlenburg R, Hensen ADO, Koopman JPR, Lamers OAC, Geurten FJA, et al. Single immunization with genetically attenuated Pf∆mei2 (GA2) parasites by mosquito bite in controlled human malaria infection: a placebo-controlled randomized trial. Nat Med. 2025 Jan 3. doi: 10.1038/s41591-024-03347-2. Online ahead of print.\u003c/li\u003e\n \u003cli\u003eOrth P, Schnappinger D, Hillen W, Saenger W, Hinrichs W. Structural basis of gene regulation by the tetracycline inducible Tet repressor-operator system. Nat Struct Biol. 2000;7(3):215-9.\u003c/li\u003e\n \u003cli\u003eGossen M, Freundlieb S, Bender G, Muller G, Hillen W, Bujard H. Transcriptional activation by tetracyclines in mammalian cells. Science. 1995;268(5218):1766-9.\u003c/li\u003e\n \u003cli\u003eLycett GJ, Kafatos FC, Loukeris TG. Conditional expression in the malaria mosquito Anopheles stephensi with Tet-On and Tet-Off systems. Genetics. 2004;167(4):1781-90.\u003c/li\u003e\n \u003cli\u003eBryk J, Reeves RG, Reed FA, Denton JA. Transcriptional effects of a positive feedback circuit in Drosophila melanogaster. BMC Genomics. 2017;18(1):990.\u003c/li\u003e\n \u003cli\u003eGong P, Epton MJ, Fu G, Scaife S, Hiscox A, Condon KC, et al. A dominant lethal genetic system for autocidal control of the Mediterranean fruitfly. Nat Biotechnol. 2005;23(4):453-6.\u003c/li\u003e\n \u003cli\u003eGossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci U S A. 1992;89(12):5547-51.\u003c/li\u003e\n \u003cli\u003eGossen M, Bujard H. Studying gene function in eukaryotes by conditional gene inactivation. Annu Rev Genet. 2002;36:153-73.\u003c/li\u003e\n \u003cli\u003eBlack WCt, Alphey L, James AA. Why RIDL is not SIT. Trends Parasitol. 2011;27(8):362-70.\u003c/li\u003e\n \u003cli\u003eFu G, Condon KC, Epton MJ, Gong P, Jin L, Condon GC, et al. Female-specific insect lethality engineered using alternative splicing. Nat Biotechnol. 2007;25(3):353-7.\u003c/li\u003e\n \u003cli\u003ePhuc HK, Andreasen MH, Burton RS, Vass C, Epton MJ, Pape G, et al. Late-acting dominant lethal genetic systems and mosquito control. BMC Biol. 2007;5:11.\u003c/li\u003e\n \u003cli\u003eWaltz E. First genetically modified mosquitoes released in the United States. Nature. 2021;593(7858):175-6.\u003c/li\u003e\n \u003cli\u003eYan Y, Scott MJ. Building a transgenic sexing strain for genetic control of the Australian sheep blow fly Lucilia cuprina using two lethal effectors. BMC Genet. 2020;21(Suppl 2):141.\u003c/li\u003e\n \u003cli\u003eBushland RC, Lindquist AW, Knipling EF. Eradication of Screw-Worms through Release of Sterilized Males. Science. 1955;122(3163):287-8.\u003c/li\u003e\n \u003cli\u003eSpinner SAM, Barnes ZH, Puinean AM, Gray P, Dafa\u0026apos;alla T, Phillips CE, et al. New self-sexing Aedes aegypti strain eliminates barriers to scalable and sustainable vector control for governments and communities in dengue-prone environments. Front Bioeng Biotechnol. 2022;10:975786.\u003c/li\u003e\n \u003cli\u003eCarvalho DO, McKemey AR, Garziera L, Lacroix R, Donnelly CA, Alphey L, et al. Suppression of a Field Population of Aedes aegypti in Brazil by Sustained Release of Transgenic Male Mosquitoes. PLoS Negl Trop Dis. 2015;9(7):e0003864.\u003c/li\u003e\n \u003cli\u003eReid W, Pilitt K, Alford R, Cervantes-Medina A, Yu H, Aluvihare C, et al. An Anopheles stephensi Promoter-Trap: Augmenting Genome Annotation and Functional Genomics. G3 (Bethesda). 2018;8(10):3119-30.\u003c/li\u003e\n \u003cli\u003eHarrell RA, 2nd. Mosquito Embryo Microinjection. Cold Spring Harb Protoc. 2024;2024(7):pdb top107686.\u003c/li\u003e\n \u003cli\u003eHarrell RA, 2nd. Mosquito Embryo Microinjection under Halocarbon Oil or in Aqueous Solution. Cold Spring Harb Protoc. 2024;2024(7):pdb prot108203.\u003c/li\u003e\n \u003cli\u003eInbar E, Eappen AG, Alford RT, Reid W, Harrell RA, Hosseini M, et al. Knockout of Anopheles stephensi immune gene LRIM1 by CRISPR-Cas9 reveals its unexpected role in reproduction and vector competence. PLoS Pathog. 2021;17(11):e1009770.\u003c/li\u003e\n \u003cli\u003ePotter CJ, Luo L. Splinkerette PCR for mapping transposable elements in Drosophila. PLoS One. 2010;5(4):e10168.\u003c/li\u003e\n \u003cli\u003ePapathanos PA, Windbichler N, Menichelli M, Burt A, Crisanti A. The vasa regulatory region mediates germline expression and maternal transmission of proteins in the malaria mosquito Anopheles gambiae: a versatile tool for genetic control strategies. BMC Mol Biol. 2009;10:65.\u003c/li\u003e\n \u003cli\u003eKojin BB, Biedler JK, Tu Z, Adelman ZN. Characterization of a female germline and early zygote promoter from the transcription factor bZip1 in the dengue mosquito Aedes aegypti. Parasit Vectors. 2020;13(1):353.\u003c/li\u003e\n \u003cli\u003eSun JS, Xiao S, Carlson JR. The diverse small proteins called odorant-binding proteins. Open Biol. 2018;8(12):180208.\u003c/li\u003e\n \u003cli\u003eHill CA, Fox AN, Pitts RJ, Kent LB, Tan PL, Chrystal MA, et al. G protein-coupled receptors in Anopheles gambiae. Science. 2002;298(5591):176-8.\u003c/li\u003e\n \u003cli\u003eLyu Z, Li Z, Cheng J, Wang C, Chen J, Lin T. Suppression of Gene Juvenile Hormone Diol Kinase Delays Pupation in Heortia vitessoides Moore. Insects. 2019;10(9).\u003c/li\u003e\n \u003cli\u003eThomas DD, Donnelly CA, Wood RJ, Alphey LS. Insect population control using a dominant, repressible, lethal genetic system. Science. 2000;287(5462):2474-6.\u003c/li\u003e\n \u003cli\u003eAlphey L, Andreasen M. Dominant lethality and insect population control. Mol Biochem Parasitol. 2002;121(2):173-8.\u003c/li\u003e\n\u003c/ol\u003e"},{"header":"Tables","content":"\u003cdiv class=\"gridtable\"\u003e\n \u003ctable id=\"Tab1\" border=\"1\"\u003e\n \u003ccaption language=\"En\"\u003e\n \u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e\n \u003cdiv class=\"CaptionContent\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eProportion of transgenic mosquitoes expressing the mBanana fluorescent protein after 24, 25 and 26 generations of selection. Only the M2i line reached homozygosity.\u003c/div\u003e\n \u003c/div\u003e\n \u003c/caption\u003e\n \u003cthead\u003e\n \u003ctr\u003e\n \u003cth align=\"left\" style=\"width: 6.1019%;\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eLine\u003c/div\u003e\n \u003c/th\u003e\n \u003cth align=\"left\" style=\"width: 14.3575%;\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eGeneration\u003c/div\u003e\n \u003c/th\u003e\n \u003cth align=\"left\" style=\"width: 21.1773%;\"\u003e\n \u003cdiv class=\"SimplePara\"\u003emBanana Positive\u003c/div\u003e\n \u003c/th\u003e\n \u003cth align=\"left\" style=\"width: 22.2541%;\"\u003e\n \u003cdiv class=\"SimplePara\"\u003emBanana Negative\u003c/div\u003e\n \u003c/th\u003e\n \u003cth align=\"left\" style=\"width: 6.8198%;\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eTotal\u003c/div\u003e\n \u003c/th\u003e\n \u003cth align=\"left\" style=\"width: 25.3553%;\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eProportion mBanana Positive\u003c/div\u003e\n \u003c/th\u003e\n \u003c/tr\u003e\n \u003c/thead\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\" rowspan=\"3\" style=\"width: 6.1019%;\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eM1f\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\" style=\"width: 14.3575%;\"\u003e\n \u003cdiv class=\"SimplePara\"\u003e24\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\" style=\"width: 21.1773%;\"\u003e\n \u003cdiv class=\"SimplePara\"\u003e174\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\" style=\"width: 22.2541%;\"\u003e\n \u003cdiv class=\"SimplePara\"\u003e54\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\" style=\"width: 6.8198%;\"\u003e\n \u003cdiv class=\"SimplePara\"\u003e228\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\" style=\"width: 25.3553%;\"\u003e\n \u003cdiv class=\"SimplePara\"\u003e76%\u003c/div\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"char\" style=\"width: 14.3575%;\"\u003e\n \u003cdiv class=\"SimplePara\"\u003e25\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\" style=\"width: 21.1773%;\"\u003e\n \u003cdiv class=\"SimplePara\"\u003e194\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\" style=\"width: 22.2541%;\"\u003e\n \u003cdiv class=\"SimplePara\"\u003e77\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\" style=\"width: 6.8198%;\"\u003e\n \u003cdiv class=\"SimplePara\"\u003e268\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\" style=\"width: 28.1766%;\"\u003e\n \u003cdiv class=\"SimplePara\"\u003e74%\u003c/div\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"char\" style=\"width: 14.3575%;\"\u003e\n \u003cdiv class=\"SimplePara\"\u003e26\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\" style=\"width: 21.1773%;\"\u003e\n \u003cdiv class=\"SimplePara\"\u003e223\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\" style=\"width: 22.2541%;\"\u003e\n \u003cdiv class=\"SimplePara\"\u003e95\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\" style=\"width: 6.8198%;\"\u003e\n \u003cdiv class=\"SimplePara\"\u003e318\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\" style=\"width: 28.1766%;\"\u003e\n \u003cdiv class=\"SimplePara\"\u003e70%\u003c/div\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\" rowspan=\"3\" style=\"width: 6.1019%;\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eM2i\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\" style=\"width: 14.3575%;\"\u003e\n \u003cdiv class=\"SimplePara\"\u003e24\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\" style=\"width: 21.1773%;\"\u003e\n \u003cdiv class=\"SimplePara\"\u003e235\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\" style=\"width: 22.2541%;\"\u003e\n \u003cdiv class=\"SimplePara\"\u003e0\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\" style=\"width: 6.8198%;\"\u003e\n \u003cdiv class=\"SimplePara\"\u003e235\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\" style=\"width: 28.1766%;\"\u003e\n \u003cdiv class=\"SimplePara\"\u003e100%\u003c/div\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"char\" style=\"width: 14.3575%;\"\u003e\n \u003cdiv class=\"SimplePara\"\u003e25\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\" style=\"width: 21.1773%;\"\u003e\n \u003cdiv class=\"SimplePara\"\u003e264\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\" style=\"width: 22.2541%;\"\u003e\n \u003cdiv class=\"SimplePara\"\u003e0\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\" style=\"width: 6.8198%;\"\u003e\n \u003cdiv class=\"SimplePara\"\u003e264\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\" style=\"width: 28.1766%;\"\u003e\n \u003cdiv class=\"SimplePara\"\u003e100%\u003c/div\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"char\" style=\"width: 14.3575%;\"\u003e\n \u003cdiv class=\"SimplePara\"\u003e26\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\" style=\"width: 21.1773%;\"\u003e\n \u003cdiv class=\"SimplePara\"\u003e323\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\" style=\"width: 22.2541%;\"\u003e\n \u003cdiv class=\"SimplePara\"\u003e0\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\" style=\"width: 6.8198%;\"\u003e\n \u003cdiv class=\"SimplePara\"\u003e323\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\" style=\"width: 28.1766%;\"\u003e\n \u003cdiv class=\"SimplePara\"\u003e100%\u003c/div\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\" rowspan=\"3\" style=\"width: 6.1019%;\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eF2c\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\" style=\"width: 14.3575%;\"\u003e\n \u003cdiv class=\"SimplePara\"\u003e24\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\" style=\"width: 21.1773%;\"\u003e\n \u003cdiv class=\"SimplePara\"\u003e197\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\" style=\"width: 22.2541%;\"\u003e\n \u003cdiv class=\"SimplePara\"\u003e60\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\" style=\"width: 6.8198%;\"\u003e\n \u003cdiv class=\"SimplePara\"\u003e257\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\" style=\"width: 28.1766%;\"\u003e\n \u003cdiv class=\"SimplePara\"\u003e77%\u003c/div\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"char\" style=\"width: 14.3575%;\"\u003e\n \u003cdiv class=\"SimplePara\"\u003e25\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\" style=\"width: 21.1773%;\"\u003e\n \u003cdiv class=\"SimplePara\"\u003e173\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\" style=\"width: 22.2541%;\"\u003e\n \u003cdiv class=\"SimplePara\"\u003e66\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\" style=\"width: 6.8198%;\"\u003e\n \u003cdiv class=\"SimplePara\"\u003e239\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\" style=\"width: 28.1766%;\"\u003e\n \u003cdiv class=\"SimplePara\"\u003e72%\u003c/div\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"char\" style=\"width: 14.3575%;\"\u003e\n \u003cdiv class=\"SimplePara\"\u003e26\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\" style=\"width: 21.1773%;\"\u003e\n \u003cdiv class=\"SimplePara\"\u003e283\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\" style=\"width: 22.2541%;\"\u003e\n \u003cdiv class=\"SimplePara\"\u003e78\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"char\" style=\"width: 6.8198%;\"\u003e\n \u003cdiv class=\"SimplePara\"\u003e361\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\" style=\"width: 28.1766%;\"\u003e\n \u003cdiv class=\"SimplePara\"\u003e78%\u003c/div\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n \u003c/table\u003e\n\u003c/div\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"parasites-and-vectors","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"parv","sideBox":"Learn more about [Parasites \u0026 Vectors](http://parasitesandvectors.biomedcentral.com/)","snPcode":"13071","submissionUrl":"https://submission.nature.com/new-submission/13071/3","title":"Parasites \u0026 Vectors","twitterHandle":"@bugbittentweets","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"em","reportingPortfolio":"BMC/SO AJ","inReviewEnabled":true,"inReviewRevisionsEnabled":true},"keywords":"Anopheles, driver line, Tetracycline, rtTA","lastPublishedDoi":"10.21203/rs.3.rs-6270709/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-6270709/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eSanaria\u0026reg; has pioneered production of aseptic, purified, vialed cryopreserved \u003cem\u003ePlasmodium falciparum\u003c/em\u003e (Pf) sporozoites (SPZ) as vaccines and for controlled human malaria infections. More than 3,500 individuals have received more than 9,700 injections of PfSPZ, worldwide. The PfSPZ are manufactured in aseptically reared female \u003cem\u003eAnopheles stephensi\u003c/em\u003e mosquitoes. Since PfSPZ vaccines are intended primarily for some of the most disadvantaged people in the world, keeping costs low is imperative. One approach to reducing cost of goods is to eliminate male mosquitoes from the production process, thereby doubling the numbers of PfSPZ-producing mosquitoes per unit space. We intend to do this by creating \u003cem\u003eA. stephensi\u003c/em\u003e with a male-lethal allele controlled by the tetracycline conditional gene expression system. Herein, we report the first step in this process, the creation of a driver line that expresses the reverse tetracycline transactivator (rtTA). After sub-optimal results using the bZip early embryonic promoter, we produced 3 mosquito driver lines that expressed rtTA from 3 different genomic loci under the early embryonic vasa promoter. Expressing the rtTA under the vasa promoter significantly increased rtTA mRNA levels compared to its level under bZip. We were unable to achieve homozygosity in two of these lines even after 26 generations. In the third line, the insertion was in an intron of a putative juvenile hormone diol kinase gene. Homozygosity was reached in this line after passage through 7 generations, indicating that the inserted vasa-rtTA nucleotides did not interfere with the function of an essential genomic locus. rtTA mRNA expression levels were higher than in the other two lines, supporting the hypothesis that failure to achieve homozygosity was not due to rtTA expression but to insertion position. The homozygous line produced\u0026thinsp;~\u0026thinsp;18% more eggs per female and a hatching rate of larvae from eggs was 39% lower than of wild-type \u003cem\u003eA. stephensi\u003c/em\u003e. The next step will be to cross the driver line with an effector line containing a male-linked lethal gene regulated by the tetracycline responsive element (TRE).\u003c/p\u003e","manuscriptTitle":"Successful insertion and expression of a tetracycline transactivator in Anopheles stephensi associated with increased egg production and decreased hatching rate","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-04-16 14:39:08","doi":"10.21203/rs.3.rs-6270709/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"Revision requested","date":"2025-04-24T10:39:07+00:00","index":"","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2025-04-24T10:06:45+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"34941147828674594097670277668870638381","date":"2025-04-02T11:48:35+00:00","index":"hide","fulltext":""},{"type":"reviewersInvited","content":"","date":"2025-03-28T11:19:46+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2025-03-26T15:10:27+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2025-03-26T15:01:28+00:00","index":"","fulltext":""},{"type":"submitted","content":"Parasites \u0026 Vectors","date":"2025-03-20T14:42:21+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"parasites-and-vectors","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"parv","sideBox":"Learn more about [Parasites \u0026 Vectors](http://parasitesandvectors.biomedcentral.com/)","snPcode":"13071","submissionUrl":"https://submission.nature.com/new-submission/13071/3","title":"Parasites \u0026 Vectors","twitterHandle":"@bugbittentweets","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"em","reportingPortfolio":"BMC/SO AJ","inReviewEnabled":true,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"7c7b86bd-5a3c-4df4-b0a5-ce0a53409a2c","owner":[],"postedDate":"April 16th, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[],"tags":[],"updatedAt":"2025-11-03T16:01:43+00:00","versionOfRecord":{"articleIdentity":"rs-6270709","link":"https://doi.org/10.1186/s13071-025-07003-7","journal":{"identity":"parasites-and-vectors","isVorOnly":false,"title":"Parasites \u0026 Vectors"},"publishedOn":"2025-10-28 15:57:55","publishedOnDateReadable":"October 28th, 2025"},"versionCreatedAt":"2025-04-16 14:39:08","video":"","vorDoi":"10.1186/s13071-025-07003-7","vorDoiUrl":"https://doi.org/10.1186/s13071-025-07003-7","workflowStages":[]},"version":"v1","identity":"rs-6270709","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-6270709","identity":"rs-6270709","version":["v1"]},"buildId":"XKTyCvWXoU3ODBz1xrDgd","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}